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Abstract 
There are a lack of valid assessment measures of anxiety and depression 
available for use with people with multiple sclerosis (MS).  As a result of few 
valid measures individuals with these mood disorders and MS have poor 
access to treatment; the true prevalence of mood disorders is unknown;  
research investigating the relationship between anxiety, depression and MS is 
limited.  Some previous attempts to validate measures of anxiety and 
depression have been conducted in this population, but these have included a 
number of methodological flaws. 
To address the concerns highlighted in the literature the current study 
attempted to validate three measures commonly used in clinical practice to 
assess depression and anxiety in people with MS. These were: the Beck 
Anxiety Inventory (BAI); the Beck Depression Inventory (BDI-II); and the 
Hospital Anxiety and Depression Scale (HADS). These measures they were 
compared to a gold standard structured clinical interview (Schedules for Clinical 
Assessment in Neuropsychiatry, SCAN) in 21 people with MS, in order to 
establish their criterion validity. 
To obtain the optimum cut off scores for each of the measures when used with 
people with MS, a receiver operating curve was conducted which plotted the 
sensitivity and specificity of each score on the measure. This new cut off score 
was transformed using SPSS to ascertain the number of cases of depression or 
anxiety in the sample using the optimum cut off score for each measure. The 
number of cases identified for depression and anxiety was compared to the 
number identified by the gold standard SCAN interview. 
Using this methodology the BAI was found not to be valid for use in people with 
MS. The BDI-II was found to be valid with a cut off score of 18 which yields high 
sensitivity (89%) and high specificity (92%). The HADS was also found to be 
valid when a cut off score of 10 was used demonstrating high sensitivity and 
specificity for both the anxiety subscale (100%, 87%) and the depression 
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subscale (78%, 92%). The reliability of each of the measures was also 
assessed and all the measures demonstrated high test-retest reliability. 
As a result of the high reliability and validity of the BDI-II and the HADS these 
measures are recommend for the use of screening for anxiety and depression 
in people with MS. It is hoped that if routine screening for depression and 
anxiety occurred in this population then access to treatment would improve. It is 
acknowledged that screening should occur in conjunction with clinical 
judgement and support. The measures that have found to be valid could also be 
used to accurately assess the prevalence of anxiety and depression in people 
with MS. This would enable the targeting of limited resources to research and 
services in areas of greatest need. Finally, valid measures would allow further 
research to be conducted to unpick the complex relationship between anxiety, 
depression and MS which could ultimately impact on the quality of life of that 
specific client group. 
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Journal Article 
 [Written for the Journal of Neurology, Neurosurgery and Psychiatry; see 
extended paper 1.1 for justification of journal choice] 
 
ABSTRACT   
In order to understand the complex nature of the relationship between 
depression, anxiety and multiple sclerosis (MS) valid assessments are needed. 
The prevalence of anxiety and depression reported varies widely dependent on 
the assessment used, although it is often reported as being high in people with 
MS. Despite the proposed high prevalence, depression and anxiety are often 
poorly identified in people with MS resulting in poor access to treatment. 
To address these issues the current study assessed the validity of three 
commonly used measures of depression and anxiety for people with MS. The 
Beck Anxiety Inventory (BAI), Beck Depression Inventory (BDI-II), and the 
Hospital Anxiety and Depression Scale (HADS) were compared to a gold 
standard clinical interview in 21 people with MS.  
The results found that the BDI-II and HADS were valid measures to detect 
depression and anxiety in people with MS. An optimum cut off score of 18 for 
the BDI-II yields high sensitivity (89%) and high specificity (92%). An optimum 
cut off score of 10 for the HADS demonstrates high sensitivity and specificity for 
both the anxiety subscale (75%, 100%) and the depression subscale (78%, 
92%). The BAI was not found to be valid. It is recommended that the measures 
BDI-II and HADS are used for screening for anxiety and depression in people 
with MS. By conducting screening it is hoped that people with MS will have 
greater access to treatment and future research can be conducted to better 
understand the relationship between depression, anxiety and MS. 
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INTRODUCTION  
Depression and anxiety are reported to have a severe impact on people with 
multiple sclerosis (MS) but they continue to be under identified.[1] Together 
these mood disorders are associated with an increase in mortality[2] and 
dramatically reduce the quality of life for those suffering from it.[3] As a result of 
under identification, access to treatment is poor[4] despite evidence that 
psychological and psychopharmacological treatments can be effective for this 
client group.[1] Poor access to treatment places individuals at risk of 
deterioration.[1] Valid measures which can be used for screening are needed 
within this population to correctly identify potential cases of depression and 
anxiety in people with MS. [See extended paper 1.2 for diagnostic criteria and 
1.3 for discussion of importance of valid assessments] 
The relationship between depression, anxiety and MS is complex. It is 
influenced by a number of factors including disability,[5] adjustment to illness[6] 
and social support.[7] Yet knowledge of the impact of each of these factors and 
how they may be best managed is limited. Research in this area is limited by 
the poor validity of the measures that are available to measures anxiety and 
depression in people with MS. [See extended paper section 1.4 for discussion 
of the relationship between depression, anxiety and MS] 
A further limitation of having a lack of valid measures available to clinicians is 
the difficulties in estimating the prevalence of anxiety and depression in people 
with MS. When using different measures the prevalence of depression in people 
with MS reported ranges from 26%[8] to 50%[9] and the prevalence of anxiety 
from 19% to 90%.[6] Valid measures would enable an accurate estimate of 
prevalence to be made and as a result, resources for research and services 
could be targeted. [See extended paper 1.5 for further discussion of varying 
prevalence rates in people with MS] 
Assessing the validity of an assessment of depression and anxiety in people 
with MS is problematic due to the complexity of the illness. For example some 
of the features of MS such as cognitive impairment[10] may potentially impact 
RQ DQ LQGLYLGXDO¶V PRRG DQG WKHUHIRUH DVVHVVPHQW RI PRRG GLVRUGHUV
Furthermore, there are commonalities in symptoms of mood disorders and MS, 
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for example, fatigue and pathological crying. These shared symptoms make 
differential diagnosis more difficult[11] and may compromise the validity of 
psychiatric assessment measures. [See extended paper 1.6 for discussion of 
complexity of assessment due to MS] 
Some attempts have been made to validate measures of anxiety and 
depression commonly used in clinical practice.[12] However many of these 
attempts have been methodologically flawed. One critical flaw is studies not 
using a gold standard comparison which is reported as necessary to assess 
criterion related validity.[13] Within psychiatric disorders the gold standard is 
considered to be a structured diagnostic interview,[14] it is this against which 
the measures in this study were validated. [See extended paper 1.7 for 
discussion of psychometric theory; 1.8 for discussion of validity and reliability]  
Aims 
The main aim of the study was to validate measures of anxiety and depression 
which are commonly used in clinical practice for use in people with MS. This 
was achieved by comparing the measures to a gold standard diagnostic 
interview. A secondary aim was to assess test-retest reliability. [See extended 
paper 1.9 for further discussion of aims] 
METHODS 
This cross-sectional study echoed a methodology used by previous studies with 
similar aims.[14] and was granted ethical approval through the Integrated 
Research Application System (IRAS) and the local NHS Trust Research and 
Development Department. [See extended paper 2.1 for discussion of design 
and methodologies used in other studies and 2.2 for discussion of ethical 
issues. See appendicles A-C for ethical approval letters] 
Participants 
Participants were recruited from two routes. Firstly from an on-going research 
projects once their active involvement with those projects was completed and 
secondly, a local database of patients with MS who had consented to be 
contacted regarding research. Any participants who had a diagnosis of MS were 
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eligible to be included in the study. Participants were excluded on the grounds 
of the diagnosis being recent (within the last three months), their current 
participation in other studies which also assessed their mood, the ability to give 
informed consent and being able to use and comprehend English. A sample 
size of 21 participants was calculated where a Kappa Coefficient was the 
outcome measure (power =.8; effect size =0.5; p<.05). [See extended paper 2.3 
for details of participants] 
Measures 
Data was gathered on demographic characteristics from each of the 
participants, including the disability level due to the MS as measured by the 
*X\¶V Neurological Disability Scale.[15] The measures to be validated by the 
study were those commonly used in adult mental health. These measures were 
then compared to a gold standard diagnostic interview. [See extended paper 
2.4 for further discussion of demographic measures used] 
 Beck Anxiety Inventory (BAI).[16] A 21 item self report inventory to 
measure the symptoms of anxiety. Participants¶ UDWH FRPPRQO\ H[SHULHQFHG
symptoms of anxiety on a four item scale resulting in a range of scores from 0 
to 63, with a score above 10 indicating anxiety.[16] The reliability and validity of 
the BAI has been widely assessed and shown to be robust.[17] Previous 
attempts to assess the validity of the measure in people with MS have been 
made by comparing it to other measures but not to a gold standard clinical 
interview.[12] [See extended paper 2.5 for further discussion of BAI] 
Beck Depression Inventory II (BDI-II).[19] A 21 item self-report 
inventory to measure the severity of depressive symptoms. It includes somatic 
and cognitive-affective symptoms of depression. Participants choose from one 
of four statements from each item to describe how they have felt during the 
previous week. Scores on the measure range from 0 to 63 with a score above 
14 indicating depression.[18] The measure has shown to be reliable and valid in 
an adult population without MS.[19] It has been validated for use in people with 
MS who have been recently diagnosed,[20] such participants were excluded 
from this study. [See extended paper 2.6 for further discussion of BDI-II] 
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 Hospital Anxiety and Depression Scale (HADS).[21] A14 item self-
report inventory where respondents answer multiple choice questions about 
their feelings in the previous week. Scores on the measure range from 0 to 21, 
with a score above 8 suggesting possible anxiety or depression.[21] The 
measure has two subscales for anxiety and depression. It has been shown to 
both reliable and valid.[22] The HADS has been compared to other measures in 
an attempt to validate it for use in people with MS[12] and has also been 
compared to a clinical interview, however, this was not in a UK population.[14] 
[See extended paper 2.7 for further discussion of HADS] 
 Gold Standard ± Structure Clinical Assessment Neuropsychiatry 
Interview (SCAN).[23] The SCAN is a structured clinical interview which maps 
onto widely used diagnostic symptoms (International Classification of Diseases 
10 (ICD-10) and Diagnostic and Statistical manual for Mental Disorders (DSM-
IV-TR)[24, 25]. Although it demonstrates adequate reliability[26] the validity of 
the measure when compared to other gold standard measures is poor.[27] The 
poor validity reflects methodological difficulties in validating a gold standard 
measure rather than an accurate assessment of the validity of the measure.[28] 
The use of the SCAN as a gold standard in previous studies further adds to the 
justification of its use in the current study.[29] The evidence suggests that less 
experienced but trained researchers can apply the SCAN reliably.[30] [See 
extended paper 2.8 for further discussion of SCAN] 
Procedure 
Potential participants were recruited as described above through their 
involvement in previous research or the local database. They were sent 
information about the study and copies of the questionnaires. Participants who 
consented to the study returned the completed measures to a research 
associate who then scored the measures. Those who had consented to 
interview had their details passed onto the researcher; this enabled the 
interview to remain blind to the questionnaire scores. The researcher completed 
the interview with the participants who provided a diagnosis of depression 
and/or anxiety using the ICD-10[24] and DSM-IV-TR[25]. Participants who had 
completed the interview were then asked to repeat the measures they had 
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completed and return them to the researcher. The results were then collated 
and analysed. [See extended paper 2.9 for further details on the information 
sent to participants; 2.10 for further discussion of procedure] 
RESULTS  
Of the 98 participants contacted for the study 24 opted into the study but only 
21 completed the questionnaires and interview. The participants were made up 
of 6 (25%) male and 18 (75%) female with a mean age of 49.25 years (standard 
deviation 9.65). The type of MS that the participants were diagnosed with was 
as follows: 58% had relapsing remitting MS, 21% had secondary progressive 
MS; 17% had primary progressive MS and 4% of participants were unsure. The 
sample was representative of the general population of people with MS in terms 
of age and gender [31] but with slightly less people with secondary progressive 
MS then would be expected[32]. Participants had received their MS diagnosis 
between 2 and 34 years prior to their involvement in the study (mean 12.13 
years; standard deviation 7.50). The range of the disability, as measured by the 
GNDS was between 3 and 38 (maximum score on the measure is 60; mean 
17.92, standard deviation 9.23). The distribution of scores did not meet the 
assumptions of a normal distribution. Any missing data was removed using pair 
wise deletion. [See extended paper 3.1 for plan of analysis, 3.2 for details of 
participant recruitment and characteristics] 
Using the original cut off points provided by the manuals for the measures 
participants identified as potential cases for anxiety were 38-52% and for 
depression was 43% (see table1; unless otherwise stated all data within tables 
relates to the baseline measurements).  A kappa coefficient was calculated and 
the agreement between the measures and the gold standard ranged from poor 
to good. The BAI demonstrated the lowest agreement with the gold standard 
(.34, p>.05). The BDI-II demonstrated the highest agreement (.81, p<.05) and 
the HADS anxiety and depression subscales showed moderate agreements 
with the gold standard (.70, p<.05 for anxiety; .61, p<.05 for depression). [See 
extended paper for 3.3 for further details of the measures] 
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Table 1  Number of cases identified in sample by measures using original cut 
off scores 
Measure Identified cases (n) Percentage 
BDI-II 9 43 
BAI 11 52 
HADS-anxiety 9 43 
HADS ± 
depression 
9 43 
SCAN - 
depression 
9 43 
SCAN ± anxiety 8 38 
 
Receiver Operating Curves 
A receiver operating curve (ROC) was used to plot the sensitivity and specificity 
of each score on the measure. The co-ordinates from the ROC curve allowed 
the optimum cut off scores to be determined for each of the measures being 
assessed. For each measure, the optimum cut off score was chosen on the 
basis that it was the score that yielded the best balance between high sensitivity 
and high specificity..[33]  
An optimum cut off score was calulated for the BAI of 10 and this yielded 
adequate sensitivity (75%) and specificity (61%; see table 2). However, when 
compared to the gold standard interview the agreement was poor and non 
signficant (Kappa coefficient =.34; p>.05). Therefore, in the current study, the 
BAI is not found to be a valid assessment of anxiety in people with MS.  
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Table 2 Co-ordinates of the ROC curve for BAI 
 
Positive if 
Less Than or 
Equal To 
Sensitivity 1-Specificity 
.5 1.00 .92 
2 1.00 .85 
3.5 1.00 .77 
5 1.00 .62 
7 .86 .54 
9.5 .75 .39 
11.5 .63 .31 
12.5 .63 .23 
13.5 .63 .15 
16 .63 .07 
19 .50 .07 
22.5 .38 .07 
26.0 .38 0 
30.5 .25 0 
37.5 .14 0 
42 0 0 
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The optimum cut off score for the BDI-II for people with MS in this study was 
found to be 18, as opposed to the score recommended by the manual of 14. 
The optimum cut off score of 18 has both high sensitivity (89%) and specificity 
(92%; see table 3). The area under the curve demonstrates the overall accuracy 
of a measure.[33] When calculated for the BDI-II the area under the curve was 
high (.98; confidence interval .93-1.03) implying that the measure is accurate. 
Using the optimum cut off score 43% of participants were identified by the 
measure as having depression, in contrast to 38% identified by the lower 
original cut off score. The agreement between the gold standard diagnosis and 
the BDI-II with the optimum cut off score was very good (Kappa coefficient =.81, 
p<.001). 
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Table 3 Co-ordinates of ROC curve for BDI-II measure 
 
 
ROC curves were conducted for both the HADS anxiety and depression sub 
scales seperately, yet a score of 10 was found to be the optimum cut off for 
both. The developers of the HADS suggested that a score of eight or above 
indicates possible anxiety or depression.[21] 
For the HADS anxiety sub scale a cut off score of 10 demonstrated high  
sensitivity (75%) and perfect specificty (100%; see table 4). Using this cut off 
Positive if Less Than or 
Equal To 
Sensitivity 1-Specificity 
.5 1.00 .83 
1.5 1.00 .75 
3 1.00 .68 
4.5 1.00 .58 
5.5 1.00 .33 
6.5 1.00 .25 
7.5 1.00 .17 
10.5 .89 .17 
18 .89 .08 
24.5 .89 0 
26.5 .78 0 
28 .67 0 
30 .44 0 
33.5 .33 0 
37 .22 0 
40 .11 0 
43 0 0 
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score 29% of the participants were identified as having anxiety from the 
measure, in contrast to the 43% found when using the cut off recommended by 
the developers of the measure.[21] The area under the ROC curve was high 
(.96; confidence interval .89 ± 1.04) which gives an overall indication that the 
measure is accurate. The agreement with the diagnosis from gold standard 
interview was very good (Kappa coefficient =.90, p<.01). 
Table 4 Co-ordinates of ROC curve for HADS anxiety subscale measure 
 
Positive if Less Than or 
Equal To 
Sensitivity 1-Specificity 
.5 1.00 .69 
1.5 1.00 .46 
3 1.00 .39 
5 1.00 .31 
6.5 .86 .23 
7.5 .86 .15 
8.5 .86 .08 
10 .86 0 
11.5 .63 0 
12.5 .50 0 
14 .38 0 
16.5 .13 0 
19 0 0 
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For the depression sub scale using the optimum cut off of 10 the sensitivity 
(78%) and specificty were also high (92%; see table 5). Using this cut off score 
33% of participants were identified as having depression from the measure, as 
oppose to the 43% participants identified using the orginal cut off score of eight. 
The area under the ROC curve was also high (96; confidence interval 88 ± 
1.03) indicating that the measure is accurate. The agreement with the diagnosis 
from the gold standard interview was good (Kappa coefficient =.70, p<.01). 
Table 5 Co-ordinates of ROC curve for HADS depression subscale 
 
Positive if Less Than or 
Equal To 
Sensitivity 1-Specificity 
.5 1 .67 
1.5 1 .5 
2.5 1 .25 
4 1 .17 
6 .89 .17 
7.5 .78 .17 
9.5 .78 .08 
11.5 .68 0 
12.5 .63 0 
13.5 .50 0 
15 .25 0 
16.5 .13 0 
18 0 0 
Page 13 of 195 
 
Once the optimum cut off scores for each of the measures had been 
determined the scores from the measures were re-classified to demonstrate the 
frequency of participants who were indicated as being positive or negative for 
anxiety and/or depression. This outcome information was placed into a 
contingency table with the outcome of the gold standard interview. The data in 
the contingency  table allowed sensitivity, specificity, positive predictitve value 
(PPV), negative predictitve value (NPV) and the discriminant ability of each of 
the measures to be calulated. This information has been summarised below 
(table 6).  
The test re-test reliability was completed for each of the measures being 
assessed. Not all the participants completed the repeat measures and as pair-
wise deletion was used the sample size was reduced to 17 participants for this 
VWDWLVWLFDO WHVW $V WKH GDWD ZDV QRW QRUPDOO\ GLVWULEXWHG D 6SHDUPDQ¶V
correlation coefficient was conducted. [See extended paper 3.5 for details of the 
assessment of reliability of the measures] 
Table 6 Summary of results 
 BAI BDI-II HADS-anxiety HADS-
depression 
Optimum cut 
off 
10 18 10 10 
Sensitivity .75 .89 .87 .78 
Specificity .61 .92 1.00 .92 
PPV .55 .88 1.00 .88 
NPV .80 .92 .93 .85 
Area under 
curve 
.81* .98* .96* .96* 
Kappa 
coefficient 
.34 .81* .90* .70* 
6SHDUPDQ¶VU .68* .93* .88* .77* 
*Significant at p<.05 level 
[See extended paper 3.4 for details of ROC and related analyses for each 
measure and 3.5 for reliability analyses] 
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DISCUSSION  
Of the measures which were assessed the BDI-II and the HADS were found to 
have good criterion validity for use in people with MS, although the optimum cut 
off scores for use in people with MS was slightly higher cut off scores then 
recommended by their manuals. The BAI was not found to be valid for the 
population. 
BDI-II 
The assessment of validity of the BDI-II has been completed before using a 
similar methodology for people with MS who had been recently diagnosed.[20] 
The study considering recent diagnosis had suggested a lower cut off score of 
13 was needed,[22] as opposed to the higher score of 18 recommended by 
these results. It may that as MS is a progressive disease[34] the factors that 
influence the relationship between depression, anxiety and MS alter over time. 
$V DQ LQGLYLGXDOV¶ OHYHO RI GLVDELOLW\ LQFUHDVHV WKH\ PD\ DOVR KDYH UHGXFHG
social support and an increase in the number of confounding symptoms (e.g. 
fatigue). An alternative explanation for the different cut off scores for people with 
MS who have been recently diagnosed[20] is the diagnosis met by the 
participants. Those with a recent diagnosis may meet the criteria for an 
adjustment disorder rather than depression.[25]  
A more recent attempt to validate the BDI-II did not compare it to a gold 
standard[12] but to other measures, which at the time, had not been validated. 
Unsurprisingly, given the lack of validation of the measures involved, poor 
agreement was found between the measures. This is in contrast to the current 
study where the measures are being compared to a gold standard clinical 
interview.  
The high reliability of the BDI-II found in the current study (.93) reflects that 
found in the previous studies[35]. Although it must be noted that there is a 
paucity of literature assessing the test-retest reliability of the BDI-II, therefore a 
large scale study would be required to have enough statistical power to 
accurately assess the test-retest reliability of the measure. 
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As a result of the good reliability and validity demonstrated by the BDI-II in the 
current study it is recommended that the BDI-II is used as screening measure 
for use with people with MS. 
HADS 
The current study is the second to validate the HADS for use in people with MS, 
although it is the first in the UK. A previous attempt by a Canadian group at 
validation concluded that the measure was valid, but that it was the optimum cut 
off score was 8 rather than 10.[14] This highlights the importance of replication 
within scientific research[36] and the caution that must be taken in generalising 
results between countries. 
Although the Canadian study did recommend a lower cut off score for use in 
people with MS than the current study both the cut off scores are within the 
range recommended by the measures developers (8-10).[21] Therefore it may 
be that those with MS need to meet the higher end of the range to indicate 
possible depression or anxiety.  
The HADS demonstrated high test-retest reliability in the current study. 
Although the test-retest reliability of the HADS has not been reported, the high 
UHOLDELOLW\KDVEHHQIRXQGVLPLODUGLVHDVHVVXFKDV3DUNLQVRQ¶V>37] 
The high reliability and validity of the HADS indicate it is a suitable measure for 
screening for anxiety and depression in people with MS. 
BAI 
 
The BAI was not found to be valid for use in people with MS.  It demonstrated 
poor agreement with the gold standard. This echoes previous studies where the 
BAI has demonstrated poor agreement with alternative measures of anxiety.[12] 
When using the BAI the frequency of participants viewed as potentially having 
anxiety was much greater than the gold standard (48% vs. 33%). This 
RYHUHVWLPDWLRQ PD\ EH GXH WR WKH PHDVXUHV¶ IRFXV RQ SK\VLFDO V\PSWRPV RI
anxiety[38] rather than a holistic consideration of all symptoms. By focusing 
exclusively on the physical manifestation of anxiety there is potentially a greater 
chance of symptoms present in both MS and anxiety confounding the measure. 
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The BAI did demonstrate good test-retest reliability, although it was below that 
of the other measures. The test-retest reliability found in the current study was 
similar to that found in previous studies[39] although it has not been assessed 
in people with MS specifically prior to the current study. 
[See extended paper section 4.1. for further discussion of the findings in the 
context of previous research] 
Strengths and limitations 
The strengths of the study are in the clinical implications and, as a result, the 
potential contribution of knowledge in understanding the relationship between 
anxiety, depression and MS. The study also demonstrated a robust 
methodology which has been shown previously to be of use in assessing the 
validity of measures. 
One of the limitations of the study is the small sample size. It is recommended 
that any replications of the study aim to increase the sample size and thus 
statistical power of the study. A second limitation is that although the study used 
a robust methodology to assess the validity of measures only one type of 
validity was assessed. The construct validity for the measures in people with 
MS is still unknown and needs to be addressed in order for the relationship 
between the constructs to be understood. [See extended paper section 4.2 for 
further discussion of the strengths and limitations] 
Clinical implications and future research 
 
This study has three important clinical implications in terms of screening and 
future research.  Firstly, screening is recommended for all those with a chronic 
physical illness,[40] this study demonstrates that the BDI-II and HADS are valid 
for use as screening measures in people with MS.  
It is hoped that by being better able to identify those who experience anxiety 
and/or depression and MS they will have be able to access treatment. It has 
already been established that there are effective treatments for those 
experiencing depression or anxiety with MS yet access to these is very poor.  
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Effective treatments for anxiety and depression could be explored further in 
future research now that valid measures are available. It is hope that the 
measures which have been found to be valid in the study can contribute to 
knowledge by enabling future research to more closely examine the complex 
relationship between anxiety, depression and MS. 
Finally, by having valid measures an accurate assessment of the prevalence of 
anxiety and depression can be made for people with MS. This would allow the 
targeting of limited resources towards areas of higher prevalence and need. 
A note of caution must be placed in implementing the recommendations from 
this study. Although it has been recommended that the BDI-II and HADS are 
used as screening measures for people with MS it should be noted that 
screening programmes have potential detrimental effects,[41] This is particularly 
because although the measures did demonstrate high sensitivity and specificity 
they were not perfect and so some people may still be misidentified. Therefore, 
any screening should be completed in conjunction with clinical judgement for it 
to be effective. [See extended paper section 4.3 for discussion of 
recommendations for future research; 4.4 for clinical implications; 4.5 for critical 
reflection and 4.6 for conclusions] 
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Extended Paper 
1. INTRODUCTION 
1.1 Justification of journal choice 
The Journal of Neurology, Neurosurgery and Psychiatry was chosen due to its 
wide readership (impact factor 4.87) which includes a relevant audience to 
disseminate the study to, such as neurologists. In addition, the journal publishes 
research regarding common neurological disorders, including multiple sclerosis 
(MS), and favours the production of articles that have direct relevance to clinical 
practice as appropriate to this study current study.  
The criteria for submission to this journal have been followed (for submission 
guidelines see: http://group.bmj.com/products/journals/instructions-for-
authors/formatting and http://jnnp.bmj.com/site/about/guidelines.xhtml).  
1.2 Diagnostic criteria 
  1.2.1 Depression. Depression is a disorder characterised by persistent 
low mood, negative self concept and changes in activity levels (Beck & Alford, 
2009). It is one of the leading causes of disability worldwide (Murray & Lopez, 
1997).  There are a number of diagnoses within the category of depression, for 
example, dysthamia is diagnosed when depressive symptomology is present for 
at least two years (American Psychiatric Association, 2000). Current prevalence 
rates for depression differ slightly between genders, with estimates of 2- 9% for 
men and 3 ± 14% for women depending on the methodology and sample used 
(Beck, 2000). More recent reviews have noted a trend in depression being 
diagnosed more commonly in younger cohorts with the onset decreasing 
towards late adolescence and early adulthood (e.g. Power, 2004). A number of 
risk factors for depression are cited in the literature, these include stressful life 
events, a family history of depression, previous depressive episodes and a poor 
social network (Carr & McNulty, 2006) 
There are two common diagnostic systems for the classification of psychiatric 
disorderes: the Diagnostic and Statistical Manual for Mental Disorders (DSM-IV-
TR; American Psychiatric Association, APA, 2000) and the International 
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Classification of Diseases (ICD-10; World Health Organisation, WHO, 1992). 
The ICD-10 is the system favoured in the UK by the National Health Service 
and the National Institute of Clinical Excellence (NICE), although in practice the 
two systems are used interchangeably (Andrews, Slade & Peters, 1999). There 
is little difference in the diagnostic criteria for depression between the two 
systems (see tables eight). Within each diagnostic category of depression there 
are a number of individual diagnoses outlined in the DSM and ICD manuals. 
This study included these individual diagnoses in the classification of  
depression. 
Traditionally depression was considered to be an acute illness with episodes 
that lasted six to nine months. However, more recent studies have 
demonstrated that the natural course of depression is more complex (e.g. 
Collaborative Depression Study; Katz & Klerman, 1979) and authors now 
suggest that relapse should be expected in depression (Carr & McNulty, 2006). 
Although many patients may recover within the first year (70%), a proportion 
may still be symptomatic five years after the onset (Boland & Keller, 2002). In 
addition once people have recovered from depression the illness is likely to 
reoccur (75% experience at least one additional episode of depression; Boland 
& Keller, 2002). 
Depression can be successfully treated through a range of models. 
Pharmacological treatments XWLOLVHDPHGLFDOPRGHONQRZQDVWKHµPRQRDPLQH
K\SRWKHVLV¶ZKLFKIRFXVHVRQDGHILFLWLQPRQRDPLQHQHXURWUDQVPLWWHUV&DUU	
McNulty, 2006). A recent meta-analysis reported that 56% of people with 
depression responded well to antidepressant medication compared to 42% 
responding to a placebo (Arroll et al., 2005). Within clinical psychology a 
number of models have attempted to address depression in different forms. For 
example, cognitive behavioural therapy (e.g. Butler, Chapman, Forman & Beck, 
2006), interpersonal therapy (e.g. Cuijpers, Straten, Andersson & van Oppen, 
DQGV\VWHPLFWKHUDSLHVHJ%DUEDWR	'¶$YDQ]RKDYHDOOVKRZQ
to be effective. Although recent reviews warn that a publication bias may have 
overestimated the effects of psychological interventions for depression 
(Cuijpers, Smit, Bohlmeiger, Hollon & Andersson, 2010). In summary, a range 
of possible treatments for depression have been shown to be successful and 
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current advice suggests a combination of pharmacology and psychological 
therapy is necessary (e.g. NICE, 2009). 
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Table 7 
Criteria for Major Depressive Episode 
DSM-IV-TR ICD - 10 
A. Five or more of following symptoms listed are 
present in same two week period with a change 
from previous functioning, at least one symptom 
being depressed mood or loss of pleasure. 
A duration of at least two weeks of both 
typical and specific symptoms 
A. Typical Symptoms: 
1. Depressed mood most of day nearly every day 1. Depressed mood 
2. Loss of pleasure or interest in all, or almost all, 
activities most of day, nearly every day 
2. Loss of interest and enjoyment 
3.  Significant weight loss or gain or decrease or 
increase in appetite nearly every day 
3. Reduced energy leading to increased 
fatigue and diminished activity 
4. Insomnia or hypersomnia nearly every day 4. Marked tiredness after only slight 
effort 
5. Psychomotor agitation or retardation nearly 
every day 
 
6. Fatigue or loss of energy nearly every day B. Specific Symptoms: 
7. Feelings of worthlessness or excessive or 
inappropriate guilt nearly every day 
1. Reduced concentration and attention 
8. Diminished ability to think or concentrate or 
indecisiveness 
2. Reduced self-esteem and confidence 
9. Recurrent thoughts of death, suicidal ideation, 
suicide attempt or specific plan 
3. Ideas of guilt and unworthiness 
B. The symptoms do not meet criteria for a Mixed 
Episode 
4. Bleak and pessimistic views of the 
future 
C. Symptoms cause significant distress or 
impairment in social, occupational, or other 
important areas of functioning 
5. Ideas or acts of self harm or suicide 
D. Symptoms are not due to substance abuse or 
a general medical condition 
6. Disturbed sleep 
E. Symptoms cannot be better accounted for by 
bereavement 
7. Diminished appetite 
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1.2.2 Anxiety. Anxiety is characterised by a feeling of fear when 
presented with a perceived threat (Rachman, 1998). Similar to depression, 
there are a range of diagnoses within the category of anxiety disorders. These 
include panic disorder, social anxiety disorder, specific phobias and obsessive 
compulsive disorder (DSM-IV-TR, APA, 2000). The criteria for anxiety disorders 
differ little between the DSM and ICD diagnostic systems (see table 
nine).Current prevalence rates vary between disorders but the overall range is 
between 1% and 15% (Carr & McNulty, 2006), with the  lifetime risk for anxiety 
disorders being approximately 15% (Kesller et al., 2005). Furthermore, like 
depression, lifetime prevalence rates seem to be increasing with higher 
prevalence rates reported in more studies (Kesller et al., 2005). Again, the risk 
of relapse is significant and has been shown to differ between genders (43% 
men; 64% women; Yonkers, Bruce, Dyck, & Keller, 2003). 
Anxiety disorders can be effectively treated using both pharmacological and 
psychological methods. Historically, pharmacological treatments have included 
the use of benzodiazepines but due to withdrawal and tolerance effects, 
prescribing practice for this group of drugs is now tightly controlled (Carr & 
McNulty, 2006). Current pharmacological treatments focus on selective 
serotonin reuptake inhibitors (SSRIs; NICE, 2004). Psychological methods that 
have been shown to be effective include cognitive behavioural therapy (e.g. 
Hofmann & Smits, 2008), acceptance based behaviour therapy (e.g. Roemer, 
Orsillo & Salters-Pedneault, 2008) and short term psychodynamic 
psychotherapies (Leichsenring, Raburg & Leibing, 2004). Current guidelines 
take the efficacy of these into account and a combination of pharmacological 
and psychological approaches is recommended (NICE, 2004). 
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Table 8 
Criteria for Generalised Anxiety Disorder 
DSM-IV-TR ICD-10 
A. Excessive anxiety and worry for 
more days than not, for at least six 
months, about a number of events or 
activities 
Primary symptoms of anxiety most 
days for at least several weeks at a 
time. 
B. Person finds it difficult to control the 
worry A. Apprehension e.g. worries about 
future misfortunes, difficulty in 
concentrating  
C. The anxiety and worry are 
associated with three (or more) of the 
following: 
Restlessness or feeling on edge; being 
easily fatigued; irritability; muscle 
tension; difficulty falling or staying 
asleep; difficulty concentrating 
D. Focus of anxiety and worry is not 
confined to another disorder (e.g. 
Social Phobia) 
B. Motor tension e.g. inability to relax, 
trembling 
E. The anxiety, worry or physical 
symptoms cause significant distress or 
impairment in social, occupational or 
other important areas of functioning 
C. Autonomic over activity e.g. light-
headedness, sweating, dizziness, dry 
mouth 
F. Disturbance is not due to mood 
disorder, psychotic disorder, pervasive 
developmental disorder, substance 
abuse or a general medical condition.  
D. Must not meet full criteria for 
depressive episode, phobic anxiety 
disorder, panic disorder, or obsessive-
compulsive disorder 
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1.2.3 Co-morbidity of anxiety and depression 
Together, depression and anxiety are common mental health problems affecting 
approximately one in six people in the UK (McManus, Meltzer, Brugha, 
Bebbington & Jenkins, 2009). Although anxiety and depression are distinct 
disorders there is difficulty distinguishing them empirically (Watson et al., 1995). 
For example, self report measures often have high correlations between anxiety 
and depression with coefficients ranging from .45 to .75 (Clark & Watson, 
1991). As a result some self report measures may demonstrate overall distress 
rather than the individual constructs of depression and anxiety (e.g. Hospital 
Anxiety and Depression Scale; Razavi, Delavaus, Faracques & Robaye, 1990; 
see section 2.7). Some of the inter-relatedness could be accounted for by an 
overlap of symptoms in a self report measure. For example, the State-Trait 
Anxiety Inventory (Speilberger, 1989) contains two items which would 
classically be asymptomatic of depression rather than anxiety: feelings of failure 
and unhappiness. Indeed, self report measures were the basis of much of the 
early research into co-morbidity of depression and anxiety (Watson, 2009). 
More recent research has utilised other methods to consider depression and 
anxiety such as FOLQLFLDQV¶ ratings (Gaynes et al., 2007) and considering  the 
constructs at a diagnostic level (e.g. Maser & Colninger, 1990). 
Different models have been developed to explain the high co-morbidity of 
depression and anxiety. Watson & Kendall (1989) suggested a two factor 
affective model, with negative affect representing a number of negative mood 
states, such as anger, sadness, and subjective distress and positive affect 
representing a number of positive mood states including joy and self 
confidence. Negative affect is present in both depression and anxiety; positive 
affect has no relationship with anxiety but is negatively correlated with 
depression (Watson & Tellagan, 1985). Thus, the absence of positive affect 
(anhedonia) can be used to distinguish depression from anxiety (Watson et al., 
1995). 
More recently, an additional factor has been added to the two factor model 
which relates exclusively to anxiety. Known as the tripartite model (Clark & 
Watson, 1991), depression and anxiety are grouped into three subtypes. In 
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addition to the negative affect of general depression experienced in both anxiety 
and depression, and the absence of positive affect unique to depression, a third 
factor of physical hyper-arousal and somatic tension is uniquely present in 
anxiety. This tripartite model has been supported empirically in different 
populations (e.g. children, Chorpita, 2002; older adults, Cook et al., 2004) and 
used to inform more specific interventions for individuals in a wide range of 
areas (e.g. targeting smoking cessation interventions according to where 
individuals fall within the model; Ameringer & Leventhal, 2010). The tripartite 
model has implications for clinical use (Buckby et al., 2008), particularly as it 
reflects the cognitive model of depression and anxiety (Nathan & 
Langenbucher, 2003). If there is an underlying general distress then treatment 
of either anxiety or depression should lead to a reduction in the other; this has 
been demonstrated in the literature (e.g. Norton, Hayes & Hope, 2004). The 
model also closely links with the current diagnostic classification of anxiety and 
depression as distinct disorders within the ICD-10 and DSM-IV-TR (Nathan & 
Langenbucher, 2003; see tables eight and nine).  
The tripartite model is has received some criticism, much of which centres on it 
not fully capturing the complexities of the two disorders. For example, Greaves-
Lord et al. (2007) found that hyper-arousal was not exclusively present in 
anxiety and could be also present in depression. In addition, the hyper-arousal 
of the anxiety factor may only be related to panic disorder and generalised 
anxiety disorder rather than other anxiety diagnoses such as social phobia and 
obsessive compulsive disorder (Watson, Gamez & Simms, 2005). In response, 
more recent models have included more complexity by taking into account 
specific symptoms of particular anxiety or depression diagnoses. For example, 
Brown and Barlow (1992) proposed a hierarchical model for anxiety disorders 
which described both a unique shared factor of anxiety and depression but also 
unique components for specific anxiety diagnoses. Other similar models, with 
both common and unique components for different diagnoses of anxiety and 
depression, have been developed (e.g. Nineka et al., 1998). 
In contrast to these categorical models, which assume depression and anxiety 
are unique constructs, a continuum model has also been developed (Haslam, 
2003). The continuum model suggests there is a single continuum which ranges 
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IURP µSXUH¶ DQ[LHW\ WR µSXUH¶ GHSUHVVLRQ 7KH FR-morbidity in the continuum 
PRGHO LV H[SODLQHG DV EHLQJ WKH PLGSRLQW EHWZHHQ µSXUH¶ DQ[LHW\ DQG
depression. The adoption of a continuum model has been called for in the 
development of the DSM-V (e.g. Kessler et al.,2003), this is in light of 
neurobiological research demonstrating specific neurotransmitters potentially 
providing a mechanistic link between depression and anxiety (Kasper, 2001). 
However, current reports suggest that the manual will continue to utilise a 
categorical approach (Fawcett, 2009). 
The current research will utilise the tripartite model of depression and anxiety to 
explain the co-morbidity. This is based on its close relationship to psychological 
models of depression and anxiety such as the cognitive model (Nathan & 
/DQJHQEXFKHUDQGLWV¶UHIOHFWLRQRIWKe current diagnostic systems.  
1.2.4 Depression, anxiety and physical health. The constructs of 
depression and anxiety may alter slightly when in different contexts. Of 
particular relevance for the current study, they may alter in people with physical 
ill health. Much of the literature considering this is from research on older adults 
(e.g. Wetherell & Arean, 1997) possibly due to the increased likelihood of 
physical ill health in this population (Katon, 2003) 
Current diagnostic criteria suggest depressive disorder cannot be diagnosed if 
the symptoms are directly related to a medical condition and that failure to take 
the physical illness into account can lead to over-diagnosis (DSM-IV; Fiske, 
Wetherell & Gatz, 2009). Conversely, the presence of physical illness may lead 
to an assumption of mental health symptoms being due to physical illness and 
thus leading to under diagnosis. In addition, it may be WKDWDQLQGLYLGXDO¶Vmood 
is a normal and understandable emotional reaction to physical ill health 
(MacHale, 2000). 
To resolve these complexities, some authors have offered alternative symptoms 
to distinguish depression from physical illness, this has varied between authors 
as different measures of depression and statistical analyses have been used. 
Moffic and Paykel (1975) utilised the Beck Depression Inventory (BDI; Beck & 
Steer, 1990) and found that there were more symptoms of hopelessness, 
anxiety psychomotor retardation, agitation and self pity in people with 
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depression and physical illness. They found no differences in physiological 
symptoms, somatic anxiety symptoms or feelings of guilt from those with 
depression and no physical illness. This was not reflected in other research, for 
example, vanHermet et al. (1993) completed psychiatric interviews with a range 
of medical and non-medical patients with depression or anxiety from the 
Netherlands. They found that the symptoms of panic, depressed mood, lack of 
confidence, sleep delay and social withdrawal distinguished those with physical 
ill health from those who were regarded as physically healthy. When they 
applied these key symptoms to a UK sample, as a predictive model of 
psychiatric disorder in people with a physical illness, they found it had high 
sensitivity (89%) and specificity (97%). The contrasting results of Moffic and 
Paykel (1975) and vanHermet et al. (1992) is repeated in a number of studies 
making similar attempts to find symptoms of mood disorders which distinguish 
people with physical illness and those without (e.g. Pinquart & Shen, 2011). 
This pattern of inconsistency continues to occur when considering specific 
physical illness. For example, one study found that those how have had a 
stroke and depression had more vegative symptoms than those with depression 
who had no stroke (Paradiso, Vaidya, Tranel, Koser & Robinson, 2008). 
However, an earlier study using similar methodology found no significant 
differences between those with and without stroke (Spalletta, Ripa & 
Caltagrione, 2005). 
One solution offered by some authors is for psychiatric criteria to be applied 
without any modifications so all symptoms will be considered, regardless of 
cause (MacHale, 2002). However, this approach is likely to increase over-
diagnosis of mood disorders in people with physical illness so some authors 
have offered specific guidelines to identify depression in physical illness (e.g. 
Hawton, mayou & Feldman, 1990). Recently, NICE have issued guidance 
regarding depression in long term physical health conditions (NICE, 2009), but 
rather than clarifying the discussion it focuses more on treatment as opposed to 
difficulties with diagnosis. 
Although some psychological models can incorporate the onset of physical 
illness as a stressful life event contributing to depression (e.g Cognitive Model 
of Depression; Beck, 2008), Kendler, Gardner & Prescott (2002) developed a 
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specific model to explain the relationship between physical illness and 
depression. This model illustrates how an individual may have a genetic 
vulnerability in addition to childhood adversity and stressful life events. When 
physical illness occurs, if individuals have unresolved attachment difficulties due 
to childhood adversity, when physical illness occurs, these people may find it 
hard to collaborate with medical due to difficulties in developing secure trusting 
relationships (Ciechanowski, Katon, Russo & Walker, 2001) and as a result, it 
may take them longer to access support (Druss, Rosenheck, Desai & Perlin, 
2002). Finally, if depression or anxiety occurs, individuals may need to make 
changes to self manage their illness (Katon, 2003).  
In summary, depression and anxiety are difficult to diagnose in people with 
physical illness and a consensus has yet to be reached on the best way to 
achieve this. In addition, once depression and anxiety occur in individuals with a 
physical illness, this can have an impact on their ability to access services, to 
interact with medical staff and to self manage their illness thus, indirectly impact 
on the illness prognosis.  
1.2.5 Multiple sclerosis (MS) diagnosis. MS is a neurological illness 
that follows an unpredictable course. It is the most common cause of non-
traumatic neurological disability amongst young and middle aged adults (Beiske 
et al., 2008). Within the UK, the prevalence is estimated to be approximately 
107 in every 100,000 people (Robertson, Deans, Fraser, & Compston, 1995), 
although there is regional variation with higher prevalence rates of MS in 
Scotland (Forbes, Wilson & Swingler, 1999). The symptoms of MS can be wide 
ranging, including impaired vision and bladder control, fatigue and cognitive 
impairment (Lezack, Howeison & Loring, 2004).  
The diagnosis of MS based is on the development of clinical symptoms over 
time (Warren & Warren, 2001). There are a number of diagnostic criteria which 
are used by different practitioners at different times (e.g. Schumacher et al., 
1965). MDQ\RI WKHPSODFHWKHGLDJQRVLVLQWR µSRVVLEOH¶ µSUREDEOH¶RU µGHILQLWH¶
categories. Despite this, due to the diversity of the disease there is a great 
potential for misdiagnosis (Burgess, 2003). 
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MS can be categorised as relapsing remitting, secondary progressive or primary 
progressive (Burgess, 2003). In relapsing remitting MS there are periods of 
acute symptoms (relapse) followed by periods of recovery (remission), making 
the course of the disease unpredictable and uncertain. Over time symptoms 
increase in severity to a point where  the criteria for secondary progressive MS 
is met and the illness begins an irreversible deterioration (Warren & Warren, 
2001). Those with primary progressive MS experience a continuous worsening 
of their condition from onset, often a gradual process. However, Burgess (2003) 
does acknowledge that within each type the prognosis and symptoms will still 
be varied.  
1.3 The importance of having valid assessments for mood disorders 
Although the literature is limited, treatments for depression and anxiety in MS 
have been shown to be effective yet individuals with MS are not currently 
screened for depression or anxiety. Thus access to treatment may be limited..  
Research has demonstrated the effectiveness of treatments for mood disorders 
in people with MS. A meta-analysis by Mohr and Goodkin (1999) concluded that 
psychotherapy and antidepressant medication are effective in reducing the 
levels of depression in patients with MS (effect size for psychotherapy r=.59, 
p<.001; for antidepressant r=.71; p<.01). Of the studies using psychotherapies, 
those which focused on coping skills were significantly more effective than 
those which were insight-orientated (z=2.25, p<.05). Mohr and Goodkin (1999) 
suggest that this may be due to the progressive nature of MS which continually 
challenges individuals¶ existing coping skills; possibly this alters as the person 
adjusts to the disease (see section 1.3.2). Only five studies met the strict criteria 
to be included in the meta-analysis. This was not sufficient to explore the 
differences between the treatment options. However, it was enough to conclude 
that if depression in MS is left untreated, it is likely to worsen. Due to the 
difficulties with meta-analysis and the strict criteria limiting the studies included, 
it may be more useful to consider individual studies. For example, cognitive 
behavioural therapy has been shown to reduce self-injection anxiety in people 
with MS (ability to self inject post-WUHDWPHQW DV PHDVXUHG E\ &RFKUDQ¶V
Q=12.25, p<.05) (Mohr, Cox, Epstein & Boudewyn, 2002). Although this pilot 
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study consisted of only eight participants, the clinical impact of reducing self-
injection anxiety is clinically significant given that the treatment for the 
symptoms of MS often requires regular injections (Mohr et al., 2002).   
Despite the reported effectiveness of treatments, access is limited. Feinstein 
(2002) interviewed people with MS and found 31% of patients with a diagnosis 
of major depression and 35% with suicidal intent had received no psychological 
help, be it medication or psychotherapy. It is difficult to draw conclusions from a 
single study but coupled with further research demonstrating that individuals 
with depression or anxiety rarely access treatment (Layard, 2006) it may be that 
these results generalise to people with MS. Of those individuals who do not 
access treatment, complications of assessment may mean those with MS are 
well represented (see section 1.6). 
The consequences of a lack of treatment can be fatal: anxiety and depression in 
people with MS has been found to correlate with suicidal intent. For example, 
Feinstein (2002) completed a structured clinical interview and the Hospital 
Anxiety and Depression Scale (HADS; Zigmond & Snaith, 1983) for a 
community sample of 140 patients with MS. They found that the lifetime 
prevalence of suicidal intent was 28.6% (Feinstein, 2002). Suicidal intent was 
found to be significantly correlated with either major depression or an anxiety 
disorder (p<.001). Unfortunately, the interpretation of the study is limited as 
sXLFLGDO LQWHQW ZDV PHDVXUHG DV RFFXUULQJ DFURVV WKH LQGLYLGXDO¶V OLIHWLPH
therefore a causal link to a diagnosis of MS cannot be determined. However, an 
HDUOLHU VWXG\ FRPSOHWHG E\ )HLQVWHLQ 2¶&RQQRU DQG )HLQVWHLQ  DOVR
demonstrated a link between suicidal intent and depression and/or anxiety. 
They  found people with MS who experienced co-morbid anxiety with 
depression had increased thoughts of suicide and self harm, somatic 
complaints and social dysfunction compared to those who experienced anxiety 
or depression alone. Although these studies have been completed by the same 
author together they highlight the need for practitioners to be aware of the risk 
of suicide in individuals with MS and co-morbid mood disorders. 
In response to these concerns Mohr & Goodkin (1999) suggest that all MS 
patients should be routinely screened for depression and that those found to be 
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depressed should be offered treatment. In light of the literature, this argument 
should be extended to include patients with anxiety; specifically those with 
injection phobias, given the severe consequences for their treatment of MS (see 
section 1.4.3). 
1.4 Relationship between depression, anxiety and MS 
Although confounding symptoms play a role in the complex relationship 
between depression, anxiety and MS (e.g. Arnett, Barwick & Beeney, 2008; 
Bradshaw & Rose, 2008) the focus in the current section is the secondary 
factors that influence the relationship (see section 1.6 for further discussion of 
the impact of confounding symptoms). There is a wealth of literature regarding 
depression and MS but relatively little that considers anxiety (Honarmand & 
Feinstein, 2009).This disparity is reflected in the present review.  
1.4.1 Adjustment to illness. Within health psychology, the concept of 
psychological adjustment is the process of adjusting to the diagnosis of a 
FKURQLF LOOQHVV DQG WKH H[SHFWHG LPSDFW RQ DQ LQGLYLGXDO¶V PRRG (Livneh & 
Antonak, 2005; see Stanton, Revenson & Tennen, 2007 for review). It has been 
demonstrated that poor psychological adjustment to illness can lead to mood 
disorders such as depression and anxiety (e.g. Ramjeet, Koutanji, Barrett, & 
Scott, 2005). This has been specifically considered in people with MS with a 
focus on individuals who have been recently diagnosed,. with a noted increase 
in prevalence following diagnosis for both depression (40%, up to two months 
after diagnosis; Sullivan, Weinshenker, Mikail & Edgley, 2008) and anxiety 
(34%, up to 24 months after diagnosis; Janssens et al., 2003). As a result of 
these high prevalence rates, attempts have been made to support people 
following a diagnosis of MS (e.g. adjustment groups for people with MS; 
Forman & Lincoln, 2010). 
Adjustment in MS is not confined to receiving the diagnosis. The illness is 
unpredictable in its course, therefore the individual is required to continually 
adjust, and some authors claim that as a result mood changes are inevitable 
(Jose Sa, 2008). In support of this, a positive relationship has been found 
between the perception of uncertainty and depression in people with MS 
(r=.559, p<.05; Gold-Spink, Sher & Theodos, 2000). 
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1.4.2 Disability. As the MS illness progresses it impacts on the 
LQGLYLGXDO¶VOHYHORIGLVDELOLW\ZKLFKmay indirectly affect their mood. It has been 
shown that, in physical illness, higher levels of disability are associated with 
higher levels of anxiety (Sareen, Cox, Clara & Asmundson, 2005). A similar 
relationship has been found with depression as disability increases in MS 
(Tsivgoulis et al., 2007; Chwastiak et al., 2002), however this finding is based 
on the use of a self report measure of disability: the Expanded Disability Status 
Scale (Kutzke, 1983). This measure has been criticised for its poor 
psychometric properties when used in people with MS (Hoogervorst, Kalkers, 
Uitdehaag & Polman, 2002). Self reports of disability are problematic given the 
finding that individuals with MS and depression rate themselves as more 
disabled on self report than is rated by their doctor (Smith & Young, 2000). 
Although this conclusion was drawn from a case series it does demonstrate the 
difficulties in using self report measures to assess disability (see section 4.5). In 
summary, although a positive correlation between severity of disability and 
mood disorders has been found the exact nature of the relationship remains 
unclear. 
1.4.3 Treatment. A clear association has been found between depression, 
anxiety and adherence to treatment for MS. Those who are experiencing 
depression or anxiety may be less likely to comply with medication regimes 
(Jared, Hancock, Arnett & Lunch, 2010). Furthermore, the medication used as 
the treatment for MS may have an impact on depression and anxiety, for 
example Interferon Beta which is used to treat MS has been associated with 
depression (Jacobs et al., 2000). Treatment of depression and/or anxiety can 
improve the treatment adherence in people with MS. For example, Mohr et al. 
(1997a) found that in treating depression participants increased their adherence 
to their treatment for MS of Interferon Beta. In another study participants with 
MS who were treated for injection anxiety significantly increased their ability to 
self inject and thus were able to more easily utilise available medication for MS 
(Cochrans Q=12.25, p<.01; Mohr, Cox, Epstein & Boudewyn, 2002)  
 1.4.4 Social support. 7KHLPSDFWRI06RQDQLQGLYLGXDO¶VPRRGPD\EH
moderated by social support. A chronic illness may lead to strained support and 
isolation as the disability impacts on the ability to access social activities 
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(Beckner, Howard, Vella & Mohr, 2010). Social support is often viewed as a 
buffer to mental health difficulties (Alloway & Bebbington, 1987). Therefore, as 
the MS progresses the social support may decrease, and thus increasing the 
risk of mental health problems. Although this has not been reserached within 
MS, it has been demonstrated in comparable chronic illnesses, for example, in 
patients with rheumatoid arthritis individuals with little social support reported 
higher levels of symptoms of both depression and arthritis (Revenson, 
Schiaffion, Magerovitz & Gibofsky, 1991). In addition positive social support has 
been shown to positively correlate with effective self management in chronic 
illness across a number of studies (see review completed by Gallant, 2003). 
However, it must be acknowledged that defining and classifying social support 
is complex thus any conclusions drawn from such studies should be taken with 
caution. 
1.5 Varying prevalence rates of depression and anxiety in people with MS 
Prevalence is the number of existing cases of a disease iQD³GHILQHGSRSXODWLRQ
DWDJLYHQWLPH´DQGLVSUHVHQWHGLQWHUPVRISHUFHQWDJH%RQLWD%HDJOHKROH	
Kjellstrom, 2006, pp.18). The reported prevalence of mood disorders within MS 
is higher than within a non-clinical population (e.g. Mohr, Hart, Julian & Tasch, 
2007). However, as will be shown, the debate continues as to how much higher 
it is. A crucial factor, when considering prevalence of mood disorders in MS 
compared to non clinical populations, is difficulty with assessment (Siegert & 
Abernethy, 2005). The current study aims to help clarify this potential source of 
confusion. 
 1.5.1 Review of the literature. To demonstrate the impact of 
assessments, a number of studies using different assessments have been 
considered (see table 9). The studies included were found using the databases 
of MEDLINE and PsycInfo, completing a keyword search using the following 
WHUPV µSUHYDOHQFH¶ µPXOWLSOH VFOHURVLV¶ DQG µDQ[LHW\¶ RU µGHSUHVVLRQ¶ LQ DUWLFOHV
published in the last fifteen years. For articles containing the woUGVµSUHYDOHQFH¶
µPXOWLSOH VFOHURVLV¶ DQG µDQ[LHW\¶  DUWLFOHV ZHUH IRXQG :KHQ WKH WHUP
µGHSUHVVLRQ¶ZDVVXEVWLWXWHGIRUµDQ[LHW\¶DUWLFOHVZHUHIRXQG7KHDEVWUDFWV
of these articles were read and many were excluded (e.g. articles published in a 
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foreign language; those not published in peer reviewed journals). If articles were 
duplicated in different journals only one copy of the article was included. In total, 
15 articles have been included. 
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Table 9 
Summary of studies assessing prevalence of depression and anxiety in people with MS 
Authors (Year) Measures used Sample Prevalence 
found 
 Comments  
Anxiety (%) Depression (%) 
Arnett & 
Randolph 
(2006) 
 
Beck Depression 
Inventory (BDI; 
Beck, Steer & 
Brown, 1996). 
  
53 patients with 
MS 
 49 (time one) 
38 (time two) 
Assessed longitudinally, three 
years apart.  
Bamer, Cetin, 
Johnson, 
Gibbons & 
Center for 
Epidemiolgoic 
Studies 
Depression Scale 
530 patients 
from East 
Washington 
 51  
 
CES-D scale is a self-report 
measure that does not provide a 
DSM-IV diagnosis (2). Used 
participants from Chwastiak et al 
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Ehde (2008) (CES-D; Radloff, 
1977) 
 
  
 
 
(2005) as reference group 
Beiske et al., 
(2008) 
Hopkins 
Symptom 
Checklist-25 
(HSC-25; 
Derogatis, 
Lipmann & Covi, 
1973). 
 
140 patients 
with MS in 
eastern Norway 
 
19.3 31.4 Large reference population 
(n=1691) but unclear if contained 
individuals with MS or other 
physical health conditions.  
Chwastiak et 
al., (2005) 
CES-D 739 participants  45.7 Participants recruited through MS 
association ± may have excluded 
those not part of association. 
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Dahl, Stordal, 
Lydersen & 
Midgard 
(2009). 
HADS SS¶VZLWK
MS, 56,000 
controls. 
Norway. 
31.1 (men) 
29.7 (women) 
26.2 (men) 
25.2 (women) 
Completed as part of wider 
population study, large number of 
µFRQWUROV¶EXWQRWFOHDULIKDGRWKHU
health conditions.  
 
Feinstein, 
2¶&RQQRU	
Feinstein 
(2002) 
 
Structured 
Clinical Interview 
for DSM-IV 
(SCID; First, 
Spitzer, Gibbon & 
Williams, 1995). 
 
42 patients with 
relapsing 
remitting MS 
 21.4 Nearly half (43%) of participants 
with depression had a past history 
of psychiatric illness prior to 
commencing treatment for MS. 
Feinstein, 
2¶&RQRU*UD\
& Feinstein 
HADS 152 participants 
with MS (107 
15.8 anxiety 
alone 
4.6 depression 
alone 
Patients recruited from local clinic 
± excluded if scheduled an 
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(1999). female).  
9.2 co-morbid 
anxiety and 
depression 
 
additional appointment. 
Korostil & 
Feinstein 
(2007). 
SCID, HADS, 
Beck Suicide 
Scale (BSS; 
Beck, Kovacs & 
Weissman, 
1979). 
 
140 clinic 
attendees with 
MS. 
Lifetime 
prevalence 
35.7 
20.5 (HADS) 
 
10.7 (HADS) Data collected from MS clinic 
sample so may not generalise to 
community sample. 
Galeazzi et 
al., (2005). 
SCID, BDI, State 
Trait Anxiety 
100 patients ± 
50 with 
 46 Found female gender and severity 
of disability were risk factors for 
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Inventory 
(Spielberger, 
1989). 
relapsing 
remitting MS, 
50 matched 
healthy controls 
depression. 
Gottberg, 
Einarsson, 
Fredikson, 
von Koch & 
Holmqvist 
(2007). 
 
BDI. 
 
166 participants 
with MS. 
Stockholm. 
 19 No reference group was used. 
Clear description of sample 
recruitment. 
McGuigan & 
Hutchinson 
(2006) 
BDI. 176 (151 
women, 60 
men) 
 35.8 Attempted to find undetected 
depression in community setting ± 
therefore excluded participants 
with diagnosis of depression. Also 
Page 44 of 195 
 
gave no clear report of how 
recruited participants. 
 
Noy et al., 
(1995) 
Hamilton Rating 
Scale for 
Depression 
(HRSD; 
Hamilton, 1960).  
Hamilton Rating 
Scale for Anxiety 
(HRSA; 
Hamilton, 1959). 
 
20 patients with 
relapsing 
remitting MS in 
Benison and 
Israel 
90 50 Excluded participants with history 
of any psychiatric illness prior to 
onset of illness or with previous or 
concurrent disabling diseases. 
Patten, Beck, 
Williams, 
Composite 
International 
136 participants  25.2 No differences found between 
treatments received. Participants 
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Barbui & Metz 
(2003). 
Diagnostic 
Interview Short 
Form for Major 
Depression 
(CIDI; Robins et 
al., 1989). 
 
recruited from Canadian public 
funding drug plan thus excluded 
those with private insurance. 
Poder et al., 
(2009) 
HADS, Social 
Phobia Inventory 
(Connor, 
Davidson, 
Churchill, 
Sherwood & 
Weisler, 2000). 
251 patients 
from clinic. 
USA. 
30 social 
anxiety (SPI).  
21 (HADS) 
9  (HADS) Modified DSM criteria for social 
anxiety to allow it to be considered 
as diagnosis when symptoms are 
OLPLWHGWRPHGLFDOFRQGLWLRQV¶VRFLDO
impact (secondary social anxiety).  
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Smith & 
Young (2000) 
BDI, HADS. 88 patients 34 (HADS) 39 (BDI)  
17 (HADS) 
Reduced the cut off score for BDI 
from 13 to 10 (see below for 
discussion).  
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To evaluate the quality of the studies that assess prevalence of mood 
disorders, guidelines for evaluating prevalence studies were considered 
(Boyle, 1988; see table 10). Using this guidance it is apparent that 
many of the studies failed on the measurement criteria as they did not 
use measures that have been found to be both reliable and valid for 
people with MS. To demonstrate the methodological difficulties in 
determining the prevalence of anxiety and depression in people with 
MS, examples of studies using different methodologies will be reported 
in detail. 
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Table 10 
Criteria to assess quality of prevalence studies 
Area  
Sampling Does the survey design yield a sample of 
respondents representative of a defined 
population? 
 Is the target population defined clearly? 
 Was probability sampling used to identify 
potential respondents? 
 Do the characteristics of respondents match 
the target population? 
Measurement Do the survey instruments yield reliable and 
valid measures of psychiatric disorder and 
other key concepts? 
 Are the data collection methods standardised? 
 Are the survey instruments reliable and valid? 
Analysis Were special features of the sampling design 
accounted for in the analysis? 
 Do the reports include confidence intervals for 
statistical means? 
 
Some studies of prevalence have compared current and lifetime 
prevalence of mood disorders in people with MS. Using the HADS and 
SCID, Korostil and Feinstein (2007) suggested a lifetime prevalence of 
35.7% for any anxiety disorder and, within this, 18.6% is accounted for 
by generalised anxiety disorder in a sample of 140 MS patients. They 
argued that anxiety disorders are common within MS but are often 
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missed and, therefore, not treated. This study used the SCID interview 
to consider lifetime prevalence and compared this with the HADS which 
assesses current mood state. Two measures were compared despite 
the fact they measure different things. This limitation meant that no 
discrimination was made between patients who had an anxiety disorder 
prior to the diagnosis of MS and those who had anxiety post diagnosis. 
As a result no conclusions about a causal relationship between anxiety 
and MS can be drawn from this study. 
A second methodological problem is if cut off scores in the measures 
used have been generalised from different populations. For example, 
Smith and Young (2000) considered 88 patients from a MS outpatient 
rehabilitation clinic. 38% of the patients gave a history of depression 
and 23% a history of anxiety. Using the standard cut off scores for 
HADS 17% met the criteria for depression (score of 8) and 34% met the 
criteria for anxiety (score of 8). When using the BDI, Smith and Young 
(2000) altered the cut off criteria and they found 39% of the same 
sample met the criteria for depression. The cut off score was altered on 
the basis of previous research conducted by Sullivan, Weinshenker, 
Mikal and Bishop (1995) which suggested a cut off score of 13 should 
be used in people with MS rather than 10. However, Sullivan et al. 
(1995) drew this conclusion from considering people with MS who had 
been newly diagnosed, yet the time since diagnosis within the Smith 
and Young (2000) study ranged from 4 to 20 years.  This highlights a 
difficulty with classical test theory as results can only be generalised to 
the population from which the sample was taken, Smith and Young 
(2000) violated this rule, thus creating difficulty in drawing conclusions 
from their analysis (see section 1.7 for further discussion of 
psychometric theory). These shortcomings highlight the need for cut off 
scores in MS and for mood disorders to be validated in a population that 
has not been recently diagnosed. 
A third methodological difficulty with the studies estimating prevalence 
is the recruitment of participants. This was demonstrated by  Feinstein 
et al. (1999). They found particularly low prevalence rates compared to 
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other studies (15.8% anxiety; 4.6% depression; 9.2% co-morbid anxiety 
and depression) which may be explained by their recruitment of 
participants; participants were assessed during their annual 
appointments at the MS clinic. However, participants who had chosen 
to make an additional appointment were excluded in order to not 
³FRQWDPLQDWH >WKH@ VDPSOH ZLWK SDWLHQWV ZKRVH DQ[LHW\ PD\ KDYH OHG
WKHP WR VHHN IXUWKHU H[DPLQDWLRQ RU UHDVVXUDQFH´ )HLQVWHLQ HW DO
1999, p.323). By adopting this recruitment process it is likely that many 
participants with anxiety were excluded. This may explain the lower 
prevalence rate found in comparison to other studies (e.g. Arnett & 
Randolph, 2006).  
 1.5.2 Prevalence of depression and anxiety in physical 
illness. It is useful to consider how depression and anxiety in MS 
compare to depression and anxiety in other physical illnesses (see 
section 1.2.3 for further discussion of the constructs of mood disorders 
in physical illness). Depression is two to three times more likely in those 
with a physical health condition than healthy adults (NICE, 2009). The 
neurological disorder of stroke is often used as a comparison for MS 
due to its similarities in variety and range of symptoms (e.g. Rickards, 
2005). Prevalence rates of depression in stroke are estimated at 
varying between 10% and 34% (Rickards, 2005). However, as outline 
above, assessment of prevalence in stroke has similar methodological 
difficulties as MS (Berg, Lonnqvist, Palomake & Kaste, 2009). Similar 
problems are present in other physical illness and some attempts have 
been made to address this with papers reviewing and critiquing the 
available assessments, for example in 3DUNLQVRQ¶V disease (Scharg et 
al., 2007). Thus, a common theme of a higher prevalence of mood 
disorders in people with physical illness is reflected across a range of 
studies. However problems with assessment continue to make accurate 
prevalence figures hard to obtain (e.g. Strober & Arnett, 2009). The 
current study is attempting to address this with people with MS. 
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1.6 Complexity of assessment due to confounding symptoms 
Anxious and depressed people with MS do not always meet the 
diagnostic criteria for depression or anxiety (see tables eight and nine). 
Clinicians may attribute confounding symptoms such as concentration 
problems entirely to MS when a portion of them could be due to 
depression or anxiety (Mohr & Goodkin, 1999). Conversely, it may be 
that symptoms of motor tension and autonomic over-activity may be 
diagnosed as generalised anxiety disorder (ICD-10, WHO, 1992) when 
they are partially or wholly due to the diagnosis of MS. Potential 
confounding symptoms will now be considered. 
The co-morbidity between depression and anxiety has been discussed 
previously (see 1.2.3) in the context of a tripartite model. When MS is 
considered as an additional co-morbidity the similarities between 
symptoms is further complicated, particularly as many measures of 
depression and anxiety overestimate somatic symptoms within physical 
health (see 1.2.4). 
In order to further understand the relationship between anxiety, 
depression and MS, a conceptual map has been developed (see figure 
one). This is based on the literature and the tripartite model (Clark & 
Watson, 1991: section 1.2.3) concerning what are likely to be the most 
common symptoms between depression, anxiety and MS. As can be 
seen there are some symptoms which are unique to each construct but 
a range which are present in two or more.  
This pattern is reflected in people with MS, where it is the somatic 
symptoms of mood disorders that are most commonly reported as 
confounding symptoms as opposed to affective and cognitive 
symptoms. Specifically, fatigue (e.g. Motl, Suh & Weikert, 2010) is a 
common symptom in MS and depression and anxiety whereas bladder 
weakness is less common. A conceptual map demonstrates the 
different symptoms and how likely it is that they are confounding. 
 
Page 52 of 195 
 
 
 
Figure One: Concept map of depression, anxiety and MS 
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 1.6.1 Fatigue. Fatigue is a common compounding symptom of 
MS and depression as it is present in both. Measures of mood that 
include an assessment of fatigue may be over-estimating the 
prevalence of depression within a MS population. However, Mohr, Hart 
& Goldberg (2003) argue that the commonly reported strong 
relationship between fatigue and depression in MS is not supported by 
empirical evidence. They suggest the over-emphasis of the relationship 
is due to, either fatigue being measured as part of both depression and 
anxiety, or due to people who are experiencing depression over-
estimating self-reported fatigue severity. In assessing this, they treated 
people with MS and depression for depression and found that the 
treatment led to an improvement in self-reported fatigue. This confirmed 
their latter hypothesis (Mohr et al., 2003). This uncontrolled study used 
three treatments: cognitive behavioural therapy, supportive group 
therapy and antidepressant medication. It is unclear if these treatments 
would reduce fatigue in people without depression (Siegert & 
Abernethy, 2005). The study demonstrates that the relationships 
between fatigue, depression and MS are more complex and multi-
faceted then earlier studies suggest (e.g. Krupp, LaRocca, Muir-Nash & 
Steinberg, 1989). 
 1.6.2 Pathological crying. Another symptom which 
demonstrates the complex nature of mood disorders and MS is 
SDWKRORJLFDO FU\LQJ 3DWKRORJLFDO FU\LQJ RFFXUV ZKHQ DQ LQGLYLGXDO¶V
emotional expression is exaggerated or contradicts the context (Parvizi 
et al., 2006) and is present in approximately one in ten people with MS 
)HLQVWHLQ )HLQVWHLQ *UD\ 	 2¶&RQQRU  ,W PD\ EH WKDW
pathological crying is unrecognised or misdiagnosed as a mood 
disorder by clinicians (Parvizi et al., 2006). Although pathological crying 
may coexist with depression, the resolution of one does not necessarily 
follow the resolution of another (Robinson, Parikh, Lipsey, Skarkstein & 
Price, 1993). Therefore, when considering the assessment of mood in 
MS, pathological crying should be considered separately (Feinstein, 
)HLQVWHLQ*UD\	2¶&RQQRU, 1997). 
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 1.6.3 Neurological symptoms. The neurological symptoms of 
MS add to the complexity of assessment of mood disorders. Overall 
impaired cognitive functioning is present within approximately 54% of 
people with MS (MacIntosh-Michaelis et al., 1991). The relationship 
between cognitive impairment and depression is well established (e.g. 
Kauhanen et al., 1999). As cognitive impairment is present within MS, it 
may be hypothesised that it would be associated with depression in this 
population. However, no such link has been widely reported 
(Brassington & Marsh, 1998). A possible explanation for this is the 
nature of the cognitive impairment, as much of the impairment within 
MS patients is in tasks that require attention resources, such as 
information processing and working memory. It has yet to be shown that 
improvement in depressive mood correlates with a reduced cognitive 
impairment in people with MS (Seigert & Abernethy, 2005). 
Rather than an overall impairment it may be more pertinent to focus on 
the specific brain lesions caused by MS and the resultant changes in 
moods. Brain lesions differ between patients, making the relationship 
between mood and brain lesions complex to assess. Zorzon et al. 
(2001) compared patients with MS, chronic rheumatoid diseases and 
healthy patients. Some moderate positive correlations were found 
between specific lesions and depression, for example, a right frontal 
lesion load positively correlated with the Hamilton Rating Scale for 
Depression (HRSD; r=.22, p<.05). No significant association between 
anxiety and Magnetic Resonance Imaging (MRI) abnormalities were 
found. This implies that anxiety is a reactive response rather than a 
condition that is linked to brain lesions. =RU]RQHWDO¶V study was 
built on by Feinstein et al. (2002), who provided more psychological 
rigour such as using a structured psychiatric interview to diagnose 
depression in patients with MS and carefully matching the samples in 
terms of demographic characteristics. They found that patients with MS 
experiencing depression, had more lesions in the left inferior medial 
frontal regions and greater atrophy of the left anterior temporal regions 
(Feisntein et al., 2002). Unfortunately, without a fuller understanding of 
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the neuropathology and neuroimaging of depression it is difficult to draw 
strong conclusions regarding the relationship between the location of 
brain lesions in people with MS and depression (Siegert & Abernethy, 
2005). 
 1.6.4 Response to confounding symptoms in assessment. In 
an attempt to acknowledge the potential confounding symptoms with 
mood disorders and MS some researchers have suggested modifying 
potential assessment measures. Mohr et al. (1997b) considered the 
items within the BDI that can be confounded by MS. They compared the 
BDI scores for a MS group, a group of patients with diagnosis of major 
depression and a student control group. They found items relating to 
fatigue, work difficulty and concerns about health contributed to 33% of 
the total BDI score in patients with MS compared with only 16.7% and 
19.2% respectively for patients within the major depression and the 
control groups. Mohr et al. (1997b) conclude that if the BDI is used in 
full it may over-estimate the prevalence of depression in individuals with 
MS (Mohr et al., 1997b). However, an attempt to replicate these results 
failed (Aikens et al., 1999) and concluded that the full item BDI should 
be used for routine assessment in people with MS. In conclusion, there 
is a lack of consensus regarding the BDI and MS and a clear study with 
a robust methodology such as the current study, is required to further 
understand how best to use the BDI for a population of people with MS. 
1.7 Psychometric theory 
Psychometric theory has developed over the past 80 years in line with 
developments in the philosophy of science (Kline, 2000; see section 
4.5). Within psychometrics two theories have developed to manage the 
inherent difficulty of assessing measures which consider internal states 
that cannot be easily verified: classical test theory and item response 
theory (Rust & Golombok, 2009). Classical test theory underpins the 
current study. 
Classical test theory suggests that, due to the imperfection of 
psychometric measures, the observed score on the measure may not 
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reflect the individuals true score. It is argued that this is because any 
observed score on a measure is made up of both the true score and an 
additional component of random error (Novick, 1966). This holds if one 
individual completes the same measure an infinite number of times or if 
there is a single administration of the same measure over a number of 
individuals (Kline, 2000). 
Much of the literature on classical test theory is devoted to managing 
the random error within observed scores. The focus is to reduce the 
random error within a measure so the observed score more closely 
reflects the true score (Kline, 2000). A number of assumptions are 
made in this process. It is assumed that errors are random, normally 
distributed and the value of the error is zero, that is, the mean of the 
distribution of errors over an infinite number of trials (Van der Linden & 
Hambleton, 2004). As a result of these assumptions classical test 
theory is unable to deal with systematic errors, such as changes in 
scores due to learning (Kline, 2000). 
Using classical test theory, a standard error of measurement can be 
calculated. This provides the standard deviation of the distribution of 
errors around the true score (Kline, 2000), which provides additional 
assumptions (Embertson & Reise, 2000). The standard error of 
measurement is considered to be consistent across a population and 
thus can be generalised to the population from which the sample was 
drawn (Emberston & Reise, 2000). The standard error is also thought to 
be the same for each score, regardless of the score. As the tests 
become longer they become more reliable, as the larger numbers of 
items (and statistics generated by them) are more stable if based on 
more items (Kline, 2000).  
Classical test theory is widely used to evaluate measures, with a focus 
on total measure scores. However, critics argue that it creates sample 
dependent statistics as the statistics only describe measures used with 
particular populations (Hambelton & Jones, 1993), thus it is difficult to 
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estimate the true score in samples that have not be tested. In response 
to this criticism more complex models have been developed.  
Item response theory considers individual items and makes more 
assumptions (Magno, 2009). It assumes an individual item score 
indicates not only the presence of a latent trait, such as depression, as 
in classical test theory, but also includes factors about the item itself. 
This has a number of consequences. Shorter measures can be viewed 
as more reliable then longer measures; the standard error of 
measurement will differ between scores but can be generalised across 
populations, and unbiased estimates of item properties can be obtained 
from unrepresentative samples (Embretson & Reise, 2000). Despite the 
advantages of item response theory, it is still considered too complex 
and technical for many researchers within psychology (Fraley, Waller & 
Brennan, 2000). 
An alternative to the item response theory is generalisabilty theory 
(Rust & Golombok, 2009). This utilises analysis of variance models to 
relate reliability and validity evaluation statistics to test application. It 
requires sources of error to be identified as test construction and a 
method of extrapolating this to the eventual use of the test (Rust & 
Golombok, 2009). Although generalisabilty theory does increase the 
conceptual clarity and precision of psychometrics it is complex, time 
consuming and expensive and thus has not been widely applied (Rust 
& Golombok, 2009).  
6RPH FULWLFV KDYH DUJXHG WKDW WKH FRQFHSW RI D µWUXH VFRUH¶ used 
throughout psychometric theory is not justified and was made to fit with 
the latent trait theory (e.g. Loevinger, 1957). These critics argue that 
observed scores cannot be split into component parts as one cannot tell 
from an observed score that anything exists in the brain and thus it is 
abstract and not of theoretical importance. There are two responses to 
this critique. First, Carnap (1962) argued that the statistical definition of 
a true score is that if an infinite number of measures of an observed 
score were averaged on the same person as the number of observed 
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scores reaches infinity the errors cancel each other out and a true score 
is obtained. Carnap (1962) argued that, although this does not occur in 
practice, it suggests that it is possible to obtain a true score from an 
observed score. Secondly, Sutcliffe (1965) argued again the critique of 
the concept of a true score by XWLOLVLQJ 3ODWR¶V WKHRU\. This suggests 
that, just because something is abstract without a physical presence, it 
GRHVQRWPHDQLWLVQRWRIDQ\XVHIRUH[DPSOHµMXVWLFH¶ 
1.8 Validity and reliability.  
The current study is concerned with assessing the concurrent validity of 
the measures in question, thus it is based within classical test theory. 
Given this, a brief description is given of the types of validity and 
reliability which are underpinned by classical test theory.  
 1.8.1 Validity 
Face Validity. The first type of validity to be considered is face 
validity. Face validity LVWKH³DFFHSWDELOLW\RIWHVWLWHPVIRUWKHRSHUDWLRQ
EHLQJFDUULHGRXW´SS5XVW	 Golombok, 2009). This type of validity 
is important, as if a participant does not feel that the measure is 
appropriate for the construct it is measuring, then they may not take the 
test seriously (Rust & Golombok, 2009). 
Content Validity. The second type of validity is content validity 
(a.k.a. criterion related or domain referenced validity). Content validity 
reflects the test specification under which the test was constructed and 
reflects the particular purpose for which the test is being developed. 
This is important because, if the measure is not reflecting the task 
specification, then it must be reflecting something else and so is a 
potential source of bias (Rust & Golombok, 2009). This assessment of 
validity reflects the functional approach to psychometric testing (as 
opposed to the trait approach; Rust & Golombok, 2009). It is the basis 
by which any test construction programme is judged and tends to be 
assessed more qualitatively than quantitatively, as any deviation from 
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the validity is more important than the degree of deviation (Rust & 
Golombok, 2009).  
Predictive Validity. Predictive validity is used wherever 
measures are used to make predictions. The correlation between the 
test score and a score on the degree of success in a selected field 
(success on the criterion) is calculated. A difficulty with predictive 
validity is that not all those selected produce a score on the criterion. 
For example, if one was attempting to assess the predictive validity of 
A-level results as a measure of degree success, those who did not 
attend university would not have a score to compare to. Therefore with 
a lack of available data the predictive validity would be under estimated. 
This difficulty is solved by using the available data and extrapolating 
downward but this is done with a level of uncertainty. 
A previous attempt at assessing this type of validity was made by 
Moran and Mohr (2005) who attempted to assess if a score on a 
measure of mood predicated the response to an intervention. Utilising 
the Hamilton Rating Scale for Depression (HRSD) and the BDI as pre 
and post measures for an intervention, they argued that by assessing 
people for depression pre and post treatment (when it was assumed 
they were not depressed) they could determine the validity of the 
measures (Moran & Mohr, 2005). They found all of the 21 BDI scores 
showed statistically significant reductions post-treatment (mean 23.7 
pre-treatment, mean 10.5 post-treatment, p<.05) and 12 of 17 HRSD 
items showed statistically significant reductions post-treatment (mean 
19.3 pre-treatment, mean 10.8 post-treatment, p<.05). The items that 
were not found to produce statistically significant lower scores post-
treatment were late insomnia, insight, psychomotor retardation and 
psychomotor agitation. This suggests that these individual items are not 
able to predict response to intervention. However Moran and Mohr 
(2005) only included participants who showed a reduction in two 
standard errors of measurement on the BDI or HRSD). As a result they 
may have excluded participants who continued to experience 
depression but it was not shown by the measure, making the 
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assumption that the measures were able to capture all cases. Moran 
and Mohr (2005) acknowledge that this does not demonstrate that the 
items in the BDI and HRSD are not confounded by MS but they do 
argue that the BDI and 12 items of the HRSD are effective in capturing 
change in depression; thus demonstrating predicative validity.  
Concurrent Validity. An assessment of the correlation between 
a new test and existing tests that purport to measure the same 
construct is known as concurrent validity. A difficulty with concurrent 
validity is that it does not address the underlying construct so, although 
two different tests may claim to measure intelligence, the fact they 
correlate does not mean that they actually measure intelligence, it just 
means the measures correlate. It also suggests that if the measures do 
not correlate then the construct validity of the measure may be 
questioned, therefore in isolation concurrent validity is not sufficient 
(Rust & Golombok, 2009). 
Of concern for the current study are previous attempts at assessing this 
type of validity. Nicholl, Lincoln, Francis and Stephan (2001) used a 
sample of 105 participants with MS who completed questionnaires to 
assess their mood. The questionnaires used were: GHQ-12, GHQ-28, 
HADS, BDI, BAI, Clinical Outcomes in Routine Evaluations (CORE-OM; 
Evans et al., 2002), and Brief Symptom Inventory. Each of the mood 
measures were found to significantly correlate with each other and the 
PHDVXUH RI GLVDELOLW\ *X\¶V 1HXURORJLFDO 'LVDELOLW\ 6FDOH 6KDUUDFN 	
Hughes, 1999). However, there was substantial variation in the rates of 
depression and anxiety depending on the measure used. Within each 
measurement manual, guidance is given on the cut off required for an 
LQGLYLGXDOWRPHHWDµFDVH¶IRUDPRRGGLVRUGHU. TKHQXPEHURI µFDVHV¶
from the different measurements are shown in table 11.  
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Table 11 
µ&DVHV¶RIPRRGGLVRUGHUIRXQGZLWKLQVDPSOH1LFKROOHWDO2001). 
Measure µ&DVHV¶LGHQWLILHGZLWKLQVDPSOH 
Anxiety Depression Unspecified 
GHQ-28   48 
HADS 16 18  
BAI 31   
BDI  28  
 
The results from this study demonstrate the large variation between the 
different subscales when used with the same population. Although this 
study compares the measures it does not provide criterion validation for 
any of the individual scales. For this to occur the scales would need to 
be compared to a gold standard assessment, such as psychiatric 
interview as suggested by Nicholl et al. (2001).The most 
methodologically sound studies aiming to assess measures concurrent 
validity are those that have compared the measures to a gold standard 
clinical interview (Sullivan, 2009). The gold standard is assumed to 
correctly distinguish between those with and without depression and/or 
anxiety.  Establishing a gold standard measurement within psychiatric 
disorders can be complex. Mental health diagnoses are based on 
subjective experiences described by the individual, this creates difficulty 
in using objective tests (Brugha, Bebbington & Jenkins, 1999). The 
most frequently cited gold standard comparison for psychiatric disorders 
in the literature is the structured psychiatric interview (e.g. Honarmand 
& Feinstein, 2009; Patten et al., 2003; Joiner, Walker, Petit, Perez & 
Cukrowicz, 2005). This is an attempt to add some objectivity to the 
clinical judgement made within an unstructured psychiatric interview.  
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Previous studies have utilised a gold standard to assess the concurrent 
validity of measures in people with MS. Mohr et al. (2007) compared the 
Patient Health Questionnaire II (PHQ; Kroenke, Spitzer & Williams, 
2003) to the structured clinical interview for the DSM-IV (SCID; First et 
al., 1995). The PHQ consists of just two items and was found to 
correctly identify 99% of participants who met the diagnosis for major 
depressive disorder (confidence interval: 91 ± 100%). However, the 
PHQ did have a high false positive rate of 27.3% so it may overestimate 
those with depression in the MS population.  
A further study was conducted by Honarmand & Feinstein (2009). They 
DOVR XVHG WKH 6&,' LQWHUYLHZ DQG FRPSDUHG WKLV WR WKH SDUWLFLSDQWV¶
responses to the HADS. They found a score of 8 on this measure 
provided good sensitivity and specificity for both depression (90% 
sensitivity, 87% specificity) and anxiety (86% sensitivity, 80% 
specificity).  
Construct Validity. A final type of validity is construct validity 
which was first proposed by Cronbach and Meehl (1955). This reflects 
the trait-related approach to psychometrics (as opposed to the function 
approach, see 1.8.4). It assesses the closeness of the measure to the 
underlying construct. Smith (2005) argues this is effectively measuring 
theory as by determining if a measure reflects construct validity one is 
examining if the measure conforms to a theory of which the construct is 
a part. Originally construct validity was based within positivist 
epistemology (see section 4.5) where theories are viewed as 
³VWUDLJKWIRUZDUGGHYLDWLRQVIURPREVHUYHGIDFWV´SS6PLWK
More recent developments in construct validity have acknowledged 
more recent epistemological understandings such as critical realism 
(see section 4.5) where theory building is viewed as an ongoing 
process. Thus, the construct validity of any measure will alter as the 
construct and theory alters and attempts to consider the construct 
validity will influence this (Smith, 2005). Therefore theories may not be 
fully proved or disproved as the debates in the theory continue to be 
tested over time. 
Page 63 of 195 
 
Smith (2005) argues that these developments in construct validity have 
allowed psychology to move away from single hypotheses to more 
comprehensive frameworks. This includes the move towards different 
ways of considering constructs within psychology that are clinically 
useful, for example a two factor affective model (see section 1.2.2). 
1.8.2 Reliability. When considering reliability, the extent to which 
the test is measured with what is purported to measure (pp.72, Rust & 
Golombok, 2009) is considered.  One needs to make the test as reliable 
as possible to take into account any variability in interpreting the test 
results. There are a number of methods to assess reliability. 
Test-retest reliability. Test-retest reliability is being assessed 
within the current study; it is assessed by giving the same measure to 
the same respondents with an interval between the two administrations. 
A correlation coefficient is calculated providing a score between zero 
and one. By basing the coefficient on the mean scores between the first 
and second administration test, it is assumed only changes in relative 
ordering or numbering points on scores can affect the result. 
Parallel Reliability. Test-retest reliability is not suitable in all 
cases. For example, if a test of knowledge is being completed people 
may learn the knowledge in the first administration so the second 
administration is influenced by memory and motivation rather than the 
knowledge being assessed. In response to this parallel forms of 
reliability are used based on classical test theory. Two versions of a test 
are created. These tests link where each item on one test has an 
alternative version on a second test. The respondent is then given both 
versions of the test and a correlation coefficient is calculated for the 
scores between the two tests. 
Although widely praised, parallel forms reliability are rarely used. This 
may be because once a test is being constructed the aim is to find the 
best possible items, so, rather than doing this twice, the items are often 
PHUJHGWRFUHDWHRQHµVXSHUWHVW¶ 
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Split half reliability. An alternative to parallel forms reliability 
that is more widely used is split half reliability. The test is split in half in 
a random fashion to create two pseudo parallel forms, so although they 
are not actually parallel no systemic bias is present in how the two 
versions are distributed. The two scores from the same respondent for 
each pseudo parallel form is then used to calculate the correlation 
coefficient.  
However, using split half reliability only provides reliability for half of the 
test not the whole test. To calculate the reliability of the whole test 
further calculations must be made. A Spearman-Brown Calculation is 
conducted. As would be expected, the reliability is always larger for the 
whole test than the correlation between the two halves because, the 
more items in the test, the more reliable it is. 
When tests are less objective, such as markers of an interview than an 
additional form of reliability is used. A correlation coefficient is 
calculated for two measures of the same interview.  
 1.8.2 Summary. There is a range of ways of assessing the 
validity and reliability of measures. The ongoing debate regarding the 
application of psychometric theory demonstrates the variety of possible 
approaches and the need to ensure the most appropriate measures are 
utilised depending on the purpose of the assessment (Rust & 
Golombok, 2009). The studies discussed demonstrate the range of 
methodologies that have been used to previously validate measures 
within a population of people with MS, with concurrent validity being the 
most frequently cited. Despite some authors concluding that there is 
currently no agreed µgold standard¶ in diagnosing mood disorders within 
MS (Seigert & Abernethy, 2005), it appears that the closest thing would 
be a structured clinical interview. As such, the most methodologically 
sound way of assessing validity of measures for people with MS 
appears to be to use a structured clinical interview as a gold standard. 
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1.9 Aims of study 
The main aim of the study was to validate measures of anxiety and 
depression for use with people who have MS. To achieve this aim 
measures commonly used in clinical practice were compared to a 
diagnostic interview in a sample from an MS population. The measures 
of mood assessed were the BDI-II, BAI and HADS. Participants¶VFRUHV
RQ WKHVH PHDVXUHV ZHUH FRPSDUHG WR D µJROG VWDQGDUG¶ PHDVXUH WKH
Structured Clinical Assessment in Neuropsychiatry (SCAN; Win, Babor, 
Brugha & Burke, 1990). 
A secondary aim was to further validate the measures of anxiety and 
depression using test-retest analysis. This would provide information on 
the test-retest reliability of the measures. 
 1.9.1 Hypotheses. There were four hypotheses that were being 
tested during the study: 
1. Participants who met criteria for depression from the clinical 
interview (SCAN) would have a score of equal to or more than 10 
on the Beck Anxiety Inventory. 
2. Participants who met criteria for anxiety from the clinical 
interview (SCAN) would have a score of equal to or more than 14 
on the Beck Depression Inventory II.  
3. Participants who met criteria for depression from the clinical 
interview (SCAN) would have a score of equal to or more than 
eight on the Hospital Anxiety and Depression Scale-Depression.  
4. Participants who met criteria for anxiety from the clinical 
interview (SCAN) would have a score of equal to or more than 
eight on the Hospital Anxiety and Depression Scale-Anxiety.  
 
The outcome of the study was expressed in terms of a Cohen's Kappa 
coefficient (1992). The number provided will give an indication of how 
each of the measures used compares with the diagnosis provided by 
Page 66 of 195 
 
the structured clinical interview. The analysis of the data is described 
within the results section (see section 3). 
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2. METHODS 
2.1 Design 
The methodology of the study employed two designs. First: a cross-
sectional within subjects design, where all participants completed the 
same measures, to assess the concurrent validity of the measures and 
to assess the additional aim of evaluating the test re-test reliability of 
the measures.  
To assess the concurrent validity of the measures they were compared 
WRDµJROGVWDQGDUG¶6XOOLYDQVHHsection 1.8). The methodology 
reflects previous studies that have similar aims (e.g. Honarmand & 
Feinstein, 2009; De Souza, Jones, & Rickards, 2009). In particular, it 
involves WKH XVH RI D GLDJQRVWLF LQWHUYLHZ DV D µJROG VWDQGDUG¶ WR
compare to instruments which have potential use as screening tools 
(e.g. Lincoln, Nicholl, Flannaghan, Leonard & van der Gucht, 2003; 
Lloyd-Williams, Friedman & Rudd, 2001; Aben, Verhey, Lousberg, 
Lodder & Honig, 2002).  
2.2 Ethical issues  
The research adhered to ethical principles outlined by the British 
Psychological Society (2009). As with all research there were risks, 
burdens and benefits for participants, these were discussed by the 
ethical committee before approval was granted for the study (appendix 
H). 
There was one clear risk to participants in the study, the potential 
distress that may be caused if they were discussing sensitive issues. 
This risk was managed by providing participants with information prior 
to obtaining consent for the study. The researcher who completed the 
interview is a trainee clinical psychologist who was able to manage 
distress if and when it arose. In addition, participants were provided  
with contact details of organisations that could help manage distress as 
part of the information pack. If a participant was identified as having 
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very high levels of anxiety or depression they were advised to contact 
their GP. This occurred with one participant. 
A burden was placed on participants in terms of time. This differed 
between participants. Completion of the questionnaires took 
approximately 50 minutes. The interview and further questionnaires 
added up to an additional 130 minutes. This was dependent on 
SDUWLFLSDQWV¶ UHVSRQVHV DW LQWHUYLHZ GXH WR WKH QDWXUH RI WKH VHPL-
structured interview if participants responded positively to some 
questions further detail was required and thus the interview took longer.  
In an attempt to reduce any further burden of time to the participants, 
the researcher travelled to the participants¶ homes to complete the 
interviews. 
A potential benefit of participating in the study included the opportunity 
to discuss the emotional distress they may have been experiencing with 
a trainee clinical psychologist who is trained to actively listen to and 
manage such distress. Participants also benefited other patients with 
MS as the study aimed to provide valid screening tools for depression 
and anxiety within this population. 
Consent was sought from participants involved in the study. It was 
assumed that all participants had the capacity to consent to the study 
unless proved otherwise (Mental Capacity Act, 2005). Participants who 
returned questionnaires were assumed to imply consent to complete 
the questionnaire measures (see section 2.3.4). Participants who did 
not return the completed measures excluded themselves from the 
study. Consent for the interviews was sought by the researcher prior to 
the interview taking place, a consent form was sent with the information 
pack and returned before the interview was conducted. Participants had 
the opportunity to discuss consent and ask the researcher questions 
both when completing the consent form and returning it by post and 
immediately prior to the interview taking place. Consent was viewed as 
a free choice and participants were able to withdraw from the study at 
any time prior to the data being analysed. 
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In order to keep the data safe and secure each participant was given a 
unique identifier code. This code was clearly labelled on any data from 
that participant; personally identifiable information has been kept 
separate from other data gathered. Specifically, consent forms have 
been kept separate and once the interviews were complete the opt-in 
slips were destroyed. All data will be securely stored at university for the 
next seven years before being destroyed. 
2.3 Participants 
 2.3.1 Recruitment. Participants were recruited from the Trent 
Region through two routes. Firstly, participants who had completed their 
involvement in an ongoing research project evaluating interventions for 
low mood in people with MS and had given permission to be contacted 
about future research were contacted. The contact details of these 
participants were left with a research associate at the University of 
Nottingham who was involved in the ongoing project.  The research 
associate passed on the contact details of these potential participants to 
the researcher and they were sent information packs regarding the 
current study (appendix H). 
As not enough potential participants were recruited through the initial 
route a second route was used. The Trent Region MS clinic routinely 
asks patients in their outpatient appointments if they would be willing to 
EHFRQWDFWHGIRUUHVHDUFK7KHVHSDWLHQWV¶FRQWDFWGHWDLOVDUHWKHQKHOG
on a database. Potential participants from this database were then sent 
information packs regarding the current study. Participants were made 
aware of the inclusion and exclusion criteria prior to them opting in to 
the study through the information sheet (see appendix H). 
2.3.2 Sample Size. A sample size of 21 was calculated for the 
study. This was based on the outcome being a Kappa coefficient, an 
effect size of 0.5, power of 0.8 and significance level of 0.05. These 
figures are based on standard use for psychological studies (Field, 
2005). The calculation was confirmed using the programme GPower3 
(³*3RZHU´10; Faul, Erdfelder, Lang & Buchner, 2009). 
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2.3.3 Inclusion criteria There only inclusion criteria for the study 
was that participants had a diagnosis of MS. The recruitment process 
ensured all potential participants had a diagnosis of MS. Participants 
were recruited either through a previous study for which MS was an 
inclusion criteria or through a database on which inclusion required a 
diagnosis of MS and attendance to a local MS clinic. 
2.3.4 Exclusion criteria. There was four criterion for the 
exclusion of participants from the study. 
Recent diagnosis of MS. Participants were excluded from the 
study if they had received a diagnosis of MS within the last three 
months. The justification for this is twofold. First, the impact of the 
diagnosis and how it is perceived by the individual may mean their 
mood state is more likely to be unstable at this point (Janssens et al., 
2003). Second, it is likely that participants who have recently been 
diagnosed would have a number of other MS related physical health 
appointments to attend and participation in a study may pose an 
additional burden.  
The assessment of this exclusion criterion was through the 
demographic questions which were sent to participants as part of the 
information pack (see appendix H). Participants were asked to state the 
time in years since the diagnosis of MS. It was planned that if 
participants indicated they had been diagnosed within the previous year 
this would be investigated further by the researcher and those who had 
been diagnosed in the last three months would be excluded. In reality, 
no participants required further investigation to establish the time since 
diagnosis of MS. 
Participation in other studies. The second criterion for 
exclusion of potential participants was if they were currently taking part 
in other studies which involved the assessment of depression and 
anxiety. This exclusion criterion was in place based on ethical 
considerations of not over-assessing participants. The assessment of 
this criterion was done through recruitment. Participants who actively 
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were taking part in a parallel study at the same site which involved the 
assessment of depression and anxiety were removed from the 
database by the research associate prior to contact details being given 
to the researcher.  
Informed consent. The third criterion was to exclude 
participants who were unable to give informed consent. Consent was 
assumed by participants who completed and returned the measures. 
For the interview, participants completed and returned consent forms 
prior to the interview being arranged and consent was discussed again 
and verbally sought immediately prior to the interview taking place (see 
section 2.2 for further details of consent). When completing the 
interview it was planned that if the researcher was concerned about the 
ability of a potential participant to give informed consent for the 
interview, it would be discussed with the clinical and research 
supervisors for the study before a decision was made. This situation did 
not arise.  
English language. Participants who were unable to understand 
or speak English were excluded. The measures in the study, including 
the interview, were in the English language. This criterion was assumed 
to have been met by those participants who were able to read the 
information pack sent to them and return the completed measures that 
were in English. 
2.4 Demographic Measures 
Participants were asked a number of demographic questions. 
Participants provided their age, gender, type of MS and the time since 
the diagnosis of MS in years. The time since diagnosis confirmed if the 
participants needed to be excluded from the study (see section 2.3.4). 
 2.4.1 Assessment of level of disability. In addition to the 
demographic questions participants were also asked to complete a 
PHDVXUH RI GLVDELOLW\ WKH *X\¶V 1HXURORJLFDO 'LVDELOLW\ 6FDOH *1'6
Sharrack & Hughes, 1999). The GNDS is a 12 item measures designed 
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specifically for people with MS (Sharrack & Hughes, 1999). Participants 
are required to answer multiple choice questions that cover different 
areas of functioning such as memory, fatigue, vision, concentration, 
speech and communication. The overall score from the measure 
(maximum 60) provides a summary of the level of impairment the 
participant experiences due to MS. This summary must be read with 
caution as it has been demonstrated that people with MS are poor at 
estimating their own level of disability (Smith & Young, 2000).  
The GNDS has demonstrated good psychometrics. It has been shown 
to have good test-retest reliability (r = .972 for the whole scale; r=.685 ± 
.987 for the 12 sections; Rossier & Wade, 2002). Although it is shown to 
be more reliable when used with an interviewer face-to-face (r=.97), this 
is marginal and it continues to be reliable when the individual self 
reports in writing (r=.90; Rossier & Wade, 2002). The validity of the 
scale was found to be good when compared to the Expanded Disability 
Scale (r=.636) and the Barthel Index (r=-.757), a measure of 
dependence in personal activities in daily living. The sensitivity of the 
GNDS has yet to be established (Rossier & Waide, 2002). 
2.5 Beck Anxiety Inventory (BAI; Beck & Steer, 1990).  
The BAI was developed to address high correlations in rating scales of 
anxiety and depression, arguing that the two disorders needed to be 
distinguished from each other (Beck, Epstein, Brown & Steer, 1986; see 
section 1.2.3 for further discussion of the co-morbidity of anxiety and 
depression). There exist a number of anxiety disorders. Although the 
BAI is designed to assess each of these it is reported to best distinguish 
those with a specific panic disorder (e.g. De Beurs, Wilson, Chambless, 
Goldstein & Feske, 1997; Leyfer, Ruberg & Woodruff-Borden, 2006). 
This potential bias to a specific disorder may result from the 
development of the measure to meet the criteria of anxiety disorders in 
the DSM-III (APA, 1987). Since then the DSM has been revised and the 
DSM-IV-TR (APA, 2000) has refined the criteria to enable clearer 
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differential diagnosis between generalised anxiety disorder and panic 
disorder (Wilson, Chambless & deBeurs, 2006). 
5HVSRQGHQWV DUH DVNHG WR UDWH V\PSWRPV RI DQ[LHW\ VXFK DV µfear of 
dying, scared or hands trembOLQJ¶This is completed using a four point 
VFDOH IURP WKHP H[SHULHQFLQJ LW µQRW DW DOO¶ during the last week to 
µseverely ± LWERWKHUHGPHDORW¶ (Beck & Steer, 1990). The developers 
recommend that a cut off score of 10 suggests mild anxiety, 19 
suggests a moderate anxiety and 30 suggests a severe anxiety (Beck & 
Steer, 1990). Although, in practice it is reported that scores of 30 and 
above are rare (Wilson et al., 2006). 
2.5.1 Reliability and validity of BAI. The reliability of the BAI 
has also been found to be good. It has been reported to demonstrate 
good internal consistency in a number of studies (e.g. De Ayala, 
Vonderharr-Carlson and Kim, 2005). The test-retest reliability is also 
reported as high (e.g. r=.71, Osman et al., 2002; r =.83, De Beurs et al., 
1997).  
The construct validity of the BAI has been evaluated through its ability 
to discriminate between anxiety and other constructs. Although the BAI 
has been found to correlate highly with measures of depression (e.g. 
BDI-II, r= .61, p< .001; Steer, Ranieri, Beck & Clark, 1993) it has been 
found to clearly discriminate from the depression construct (e.g. De 
Beurs et al, 1997). This is unsurprising given it was a key aspect of the 
development of the BAI (Wilson et al., 2006). The ability of the BAI to 
PHDVXUH WKH FRQVWUXFW RI DQ[LHW\ KDV FRPH XQGHU FULWLFLVP GXH WR LWV¶
omission of potential cognitive components of the construct, for 
example, worry (Wilson et al., 2006). However as mentioned previously, 
this critique does not take into account the cognitive elements present 
LQWKHVFDOHVXFKDV³IHDURIG\LQJ´ 
Criterion validity, particularly concurrent validity, is high in the BAI. The 
BAI has been shown to have correlations with other established 
measures of anxiety, for example, when compared to the Hamilton 
Anxiety Rating Scale (HARS; r=.56, p<.001, Beck & Steer, 1991), the 
Page 74 of 195 
 
SCL-90-R anxiety subscale (r=.81, p<.001; Steer et al., 1993) and the 
State Trait Anxiety Inventory (r=.58, p<.00; Fydrich, Dowdall & 
Chambless, 1992). Unsurprisingly, given its development when 
compared to a structured clinical interview based on the DSM-II (e.g. 
SCID), the BAI performs well when using the suggested cut off of 10 
(sensitivity 76%, specificity 65%; Eack, Singer, & Greeno, 2008). 
 2.5.2 Use of BAI in people with MS. The BAI has previously 
been assessed for concurrent validity in people with MS by comparing it 
with other measures. It was found to correspond poorly with both the 
HADS (kappa coefficient= .33, p<.0001) and the GHQ-12 (kappa 
coefficient= .30, p<.005; Nicholl et al., 2001). The validity of the BAI has 
not been compared to a gold standard assessment of a clinical 
interview in people with MS. 
As with the other measures being assessed there is a confounding of 
symptoms between anxiety and MS (see section 1.6). Although this has 
not been specifically addressed by researchers using the BAI in a 
sample of people with MS, the BAI has been considered in people with 
other physical health problems. For example, older adults with medical 
problems :HWKHUHOO 	 $UHDQ  DQG 3DUNLQVRQ¶V GLVHDVH ZKHUH
concerns have been raised that the BAI overestimates the prevalence 
of anxiety (Higginson, Fields, Koller & Troster, 2001). 
2.6 Beck Depression Inventory-II (BDI-II; Beck, Steer & Brown, 
1996).  
The BDI-II is the most widely applied clinical and research measure of 
depressive symptoms (Aikens et al., 1999). It was developed as a 
revised version of the Beck Depression Inventory (BDI; Beck, Ward, 
Mendelson, Mock, & Erbaugh, 1961). The BDI-II is designed to 
correspond with the DSM-IV-TR criteria for a major depressive episode 
(APA, 2000) and LV UHFRPPHQGHG DV WKH ³SUHPLHU LQVWUXPHQW´ IRU WKH
assessment of severity of depressive symptoms (Joiner et al., 2005, 
p.274) 
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To complete the measure participants indicate their agreement with one 
of four statements across 21 items. For example, participants are asked 
DERXWWKHLUIHHOLQJRIIDLOXUHE\PDUNLQJRQHRIIRXUVWDWHPHQWVµI do not 
feel like I failure; I have failed more than I should have; As I look back I 
see a lot of failures; I feel a total failure as a person¶%HFNHWDO
The measure is noted for its easy administration and scoring, (Hagen, 
2007). The manual for the measure suggests that a score of 14 ± 19 
indicates a mild depression, 20 ± 28 moderate and 29 ± 63 severe 
depression (Beck et al., 1996). This scoring pattern has been criticised 
IRUEHLQJµERWWRPKHDY\¶+DJen, 2007). 
2.6.1 Reliability and validity of BDI-II.  The reliability of the 
BDI-II is high (Hagen, 2007). Reviews of the psychometric properties of 
the BDI-II UHSRUWKLJK LQWHUQDOFRQVLVWHQF\ Į!  -RLQHUHWDO
based on studies conducted by the developers of the measure (e.g. 
Steer, Rissmiller & Beck, 2000). 
The construct validity of the BDI-II has been considered through 
conducting factor analyses. When developed the BDI-II loaded onto two 
factors, a cognitive factor and a somatic-affective factor (Beck et al., 
1996). The finding of these two factors has been replicated with a 
number of groups including primary care patients (Arnau, Meagher, 
Norris & Bransom, 2001) and adolescents (Steer, Geetha, Ranieri, & 
Beck, 1998). Although alternative models (with between one and four 
IDFWRUVKDYHEHHQVXJJHVWHGWKHWZRIDFWRUPRGHOUHPDLQVZHOO³VXLWHG
to the assessPHQW RI GHSUHVVLRQ GLPHQVLRQV´ 9DQKHXOH 'HVPHW
Groenvynk, Rosseel & Fontaine, 2008, pp.183).  
The BDI-II has demonstrated strong criterion validity. This has been 
assessed by comparing the BDI-II to established alternative measures 
of depression. These have included a structured clinical interview (r=  
.83, p<.05, Sprinkle et al., 2002), the CES-D (r = .68, p<.001, Segal, 
&RROULGJH&DKLOO	2¶5LOH\DQG0RQWJRPHU\$VEHUJ'HSUHVVLRQ
Rating Scale (r=.869, p<.0001; Svanborg & Asberg, 2001). 
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 2.6.2 Use of BDI-II in people with MS. A previous attempt at 
validating the BDI-II has been completed in people with MS using a 
clinical interview as a gold standard (Sullivan et al., 1995). Following 
this study an alternative cut off score for the BDI-II of 13 was 
suggested, demonstrating sensitivity of 71% and specificity of 79% 
(Sullivan et al., 1995). However, this study only included participants 
who had been recently diagnosed andthere is likely to be a difference in 
those who have not recently been diagnosed (Janssens et al., 2001).  
Generalising to a population from which the sample was not originally 
taken violates classical test theory assumptions and so the results of 
this study cannot be generalised to all people with MS (see section 1.7) 
As described previously (Section 1.8) an attempt at validating the BDI-II 
for participants with MS who had not recently been diagnosed was 
made by Nicholl, Lincoln, Francis and Stephan (2001). The BDI-II was 
not compared to a gold standard and showed poor agreement with the 
HADS (kappa = .12, p>.2; Nicholl et al., 2001). 
The psychometric properties of the BDI-II have also been tested in 
samples which may be comparable to people with MS. This has 
addressed concerns about the inclusion of somatic items for a sample 
with physical health problems due to the overlap of symptoms. For 
example, inclusion of somatic items was supported in participants with 
chronic pain due to the item total correlations with chronic pain (e.g. 
loss of energy; r = .53; +DUULV	'¶(RQ 
2.7 Hospital Anxiety and Depression Scale (HADS; Zigmond & 
Snaith, 1983).  
The HADS was developed to assess anxiety and depression in non-
psychiatric patients with physical health problems (Zigmond & Snaith, 
 'HVSLWH LWV¶ DLP RI LQFUHDVLQJ GLDJQRVWLF DFFXUDcy through the 
omission of somatic symptoms (Snaith, 2003) a recent meta-analysis 
found alternative measures perform as well as the HADS in medical 
populations (e.g. BDI; Brennan, Worrall-Davies, McMillan, Gilboody & 
House, 2010). The HADS has also been criticised for its exclusion of 
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terms as the severe end of the depression spectrum (e.g. suicidal 
ideation and psychotic features; Schrag et al., 2007). 
Although it has been criticised the HADS continues to be a widely used 
measure in both research and clinical practice (Bjelland, Dahl, Haug & 
Neckelmann, 2002). Respondents are required to answer 14 multiple 
choice questions about how they have been feeling over the previous 
week. For example, , IHHO WHQVHRU µZRXQGXS¶scoring in a range from 
most of the time to not at all.  The measure is split into two subscales of 
anxiety and depression where the authors suggest a score above eight 
in both subscales indicates the potential of a disorder and 10 indicating 
a diagnosis (Zigmond & Snaith, 1983). 
2.7.1 Reliability and validity of HADS. The reliability of the 
HADS has been assessed in a large non-clinical sample of 1792 
participants and found to indicate adequate internal consistency with 
the anxiety and depression subscales being moderately correlated 
(0.53; Crawford, Henry, Crombie and Taylor, 2001).  
The HADS was developed as having a two dimensional construct of 
depression and anxiety (Zigmond & Smith, 1983). However both factor 
analyses (Martin, 2005) and the use of a Rasch model (Pallant & 
Tennant, 2007) have questioned this assumption. One of the items in 
particular is problematic: item seven, I can sit at ease and feel relaxed. 
This item is labelled as loading onto the anxiety subscale but has been 
found to correlate higher with the depression subscale (e.g. Mykletun, 
Stordal & Dahl, 2001). As a result of this confusion some authors 
suggest the total score of the HADS should be used as a measure of 
psychological distress rather than two separate scores of depression 
and anxiety (e.g. Razavi et al., 1990). 
Bjelland et al. (2002) reviewed studies that reported the concurrent 
validity of the HADS. In comparison to other measures the HADS has 
demonstrated high correlations (e.g. in comparison to BDI, r= .6 - .8; 
Bjelland et al., 2002). Since this review further studies have been 
published adapting and validating the HADS for specific client groups 
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where it has continued to demonstrate robust psychometrics (e.g. 
intellectual disabilities, Dagnan et al., 2008). 
2.7.3 Use of HADS in people with MS. The HADS has been 
used in people with MS previously where it has been found to be less 
sensitive when compared to other measures of anxiety and depression 
(e.g. Nicholl et al., 2001), for example, when compared to the BDI-II it 
the HADS-depression subscale was found to have just 25% sensitivity 
(Nicholl et al., 2001).  
The validity of the HADS has been assessed in people with MS by 
comparing it to a gold standard clinical interview. It was found that the 
advised cut off score of 8 provided high sensitivity and specificity for 
depression (sensitivity: 90%, specificity: 87.3%) and generalised anxiety 
disorder (sensitivity: 88.5%, specificity: 80/7%) (Honarmand & 
Feinstein, 2009). This study was conducted on a Canadian population 
where the prevalence rate for MS (>50 per 100,000, Poppe, Wolfson & 
Zhu, 2008) is lower than the UK (107 per 100,000; Robertson et al., 
1995) and has not been replicated in the UK.  
2.8 Gold Standard Measure: Structured Clinical Assessment in 
Neuropsychiatry (SCAN; Win et al., 1990).  
As stated previously the gold standard measure for a psychiatric 
diagnosis is a structured clinical interview (section 1.8.1). There exist a 
number of such interviews (e.g. Composite International Diagnostic 
Interview, CIDI, Robins et al., 1989; Structured Clinical Interview for 
DSM-IV, SCID, First et al., 1997) which are similar in nature (Brugha, 
Jenkins, Taub, Meltzer & Babbington, 2001).  The SCAN was chosen 
for the current study.  
 2.8.1 Justification for choice of measure. In contrast to some 
alternatives (e.g. CIDI) the SCAN requires that each criterion is being 
met currently (Brugha et al., 2001). As a result the SCAN is more likely 
to map onto the measures being assessed which considers the 
experiences of participants up to a maximum of two weeks prior to the 
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measure being completed. Although structured, the small amount of 
flexibility within the SCAN does prevent underreporting of symptoms 
(Eaton, Neufield Chen & Cai, 2000). 
Pragmatically, the training required to complete the interviews reliably 
was more accessible to the researcher than the possible alternative 
interviews. The SCAN also maps on to two diagnostic systems, the 
ICD-10 (WHO, 1992) and the DSM-IV (APA, 2000).  Alternatives only 
map onto the latter. This was felt to be important as the measures being 
validated against it were to be used in the NHS which favours the ICD-
10 system (e.g. NICE, 2009). 
Furthermore and importantly for the current study, Rijiners et al., (2000) 
confirmed research that less experienced but trained interviewers can 
apply the SCAN reliably (Brugha, Neinhuis, Bagghi, Smith & Meltzer, 
1999). The researcher has limited experience of using the SCAN but 
did complete the training recommended to use the instrument.   
 2.8.3 Reliability and Validity of SCAN. The SCAN has 
substantial test-retest reliability for identifying if an individual met a level 
RI GLDJQRVWLF µFDVHQHVV¶  5LMLQHUV HW DO  )RU WKH VSHFLILF
diagnoses being assessed in the current study the test-retest reliability 
also remained good (.52 for depression and .49 for anxiety disorders; 
Rijiners et al., 2000). 
The complexity of assessing validity in a gold standard measure has 
caused some authors to question the validity of the structured clinical 
interview (e.g. Leeman, 1998). The most common way is to assess 
YDOLGLW\E\WKHPHDVXUHV¶³FDSDFLW\WRUHDFKDGLDJQRVLVHTXLYDOHQWZLWK
WKH GLDJQRVHV UHDFKHG E\ RWKHU SURFHGXUHV RI NQRZQ YDOLGLW\´
(Rosenman, Korton & Levings, 1997, pp.582).  This has been achieved 
by comparing one gold standard with another. For example, the SCAN 
has been compared to the CIDI (Brugha et al., 2001). The agreement 
between the two interviews was poor when considering depression and 
anxiety diagnoses (kappa =.43; Brugha et al., 2001). However, less 
than half of the participants in the study (44%) completed both 
Page 80 of 195 
 
interviews as the majority of participants completed only either the 
SCAN or the CIDI, making comparisons between the measures in the 
same participants difficult. This echoes poor agreement found 
previously in similar comparison studies (e.g. .28 ± .62; Andrews, 
Peters, Guzman & Bird, 1995). The poor agreement reflects both the 
methodological difficulties in assessing validity for a gold standard 
measure in psychiatry (Rosenman et al., 1997) and is similar to that 
found when other measures are compared (e.g. SCID and Personality 
Disorder Examination yielded kappa of diagnostic agreement of .38; 
2¶%R\OH	6HOI 
 2.8.4 Use of the SCAN as a gold standard. Although the SCAN 
has not been used to validate measures in participants with MS, it has 
been used as a gold standard in a number of studies. This has included 
psychiatric disorders (Bech, Rasmussen, Olsen, Noerholm & 
$ELOGJDDUG  VWURNH /LQFROQ HW DO  3DUNLQVRQ¶V GLVHDVH
(Leentjens, Verhey, Lousberg, Spitsbergen, & Wilmink, 2000) and 
+XQWLQJWRQ¶VGLVHDVH'H6RX]DHWDO, 2009).  
2.9 Information packs sent to participants 
The information packs sent to the participants provided them with 
information about the study, measures to complete, a consent form and 
opt-in slips. A cover letter explained to the participant about the study 
and why they had been invited to become involved (appendix E). An 
information sheet, written by the researcher, included information about 
the aims of the study, the risks and benefits of involvement and contact 
details for participants (appendix H). Personal contacts of the 
researcher who have MS were asked to confirm the information sheet 
was understandable. 
A consent form was included for participants to complete if they wished 
to take part in an interview (appendix F). Opt-in slips were used for 
participants to provide contact details for either interviews or to request 
a summary of results once the study was complete (appendix G). 
Finally, the information packs also contained copies of each of the 
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measures used in the study as well as a stamped addressed envelope 
for the participants to return the questionnaires to the research 
associate.  
2.10 Procedure 
Participants were recruited as outlined above. Those who consented to 
participation in the research returned the completed measures and an 
opt-in slip to a research associate. The research associate scored the 
measures and passed on contact details of participants who had 
consented to an interview with the researcher. This allowed the 
researcher to be blind to the questionnaire scores when conducting the 
interview. 
The researcher then contacted these participants to arrange an 
interview. The diagnostic interview (SCAN) was completed at a time 
and place convenient to the participant and recorded with a digital voice 
recorder. The recording of the interviews allowed the researcher to 
listen back to the interview in order to confirm the responses to the 
TXHVWLRQV 7KH UHVHDUFKHU UHPDLQHG EOLQG WR WKH SDUWLFLSDQWV¶
questionnaire scores. The interview allows diagnosis of depression 
and/or anxiety using the ICD-10 and DSM-IV-TR. The recordings of the 
interviews were copied, clearly labelled and stored securely at a 
university base. Following the interview, the participants repeated the 
initial baseline measures and returned them to the researcher. This 
extra data allowed the analysis of the test-retest reliability of the 
measures being assessed. 
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3. RESULTS 
3. 1 Plan of analysis 
The aim of the study was to validate measures of anxiety and 
depression for use with people who have MS (see section 1.9 for further 
discussion of aims). To achieve this, the analysis assessed if the BDI, 
BAI and HADS would differentiate between those who were seen to 
have depression/anxiety and those who were not as measured by the 
SCAN interview. A Receiver Operative Characteristic (ROC) analysis 
was conducted which allowed the identification of potential new cut off 
scores for the measures being assessed. 
Further analysis was conducted to evaluate the test-retest reliability of 
WKH PHDVXUHV EHLQJ DVVHVVHG 7KLV ZDV GRQH XVLQJ 3HDUVRQ¶V
correlation coefficient (Pallant, 2006).All analysis was conducted using 
SPSS for Windows version 16.0 (released September 2007). 
3.1.2 Missing Data. Where there was missing data in the study 
pair wise deletion was used, whereby the case is excluded from 
calculations for which there is no score (Field, 2000). Two alternatives 
to handle missing data are list wise deletion or replacing the missing 
values with the mean value for the sample (Pallant, 2006). List wise 
deletion would have excluded cases with missing data from any 
analyses and thus reduced the sample size dramatically (Field, 2005). 
Replacing the missing values with the mean value for the sample is 
advised against in small samples as it suppresses the true value of the 
standard deviation (Field, 2005). 
All of the participants were asked to repeat the measures following the 
interview. However, only 17 (81%) participants returned the completed 
measures to the researcher. Participants who did not repeat the 
measures were excluded from analyses of the data regarding repeated 
measures.   
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3.2 Participant recruitment and characteristics 
 3.2.1 Recruitment. In total, 98 potential participants were sent 
information packs regarding the study. Of these participants, 24 opted 
into the study and all the participants met the inclusion criteria. 21 
participants were interviewed, one participant declined an interview 
when contacted and two participants were not able to be contacted prior 
to the deadline set for data collection. A flow chart of the recruitment of 
participants is shown in figure two.
 
Figure two: Flow chart of recruitment 
Participant sent 
information pack 
(n=98) 
Paritipant returned 
completed 
measures 
(n=24) 
Participant 
opted in and 
completed 
interview 
(n=21) 
Participant 
returned 
repeated 
measures 
(n=17) 
Participants chose to 
recieve summary of 
results 
(n=18) 
Participant did 
not return 
repeated 
measures  
(n=three) 
Paritcipant 
declined 
interview or did 
not respond 
(n=three) 
Paritcipant 
declined to be 
involved in study 
(n=74) 
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3.2.2 Participant Characteristics. Demographic information 
was gathered from participants. The sample consisted of 24 
participants: six male (25%) and 18 female (75%). Participants provided 
details of the type of MS they had been diagnosed with: 14 (58%) of 
participants had relapsing remitting MS, five (21%) had secondary 
progressive MS and four (17%) had primary progressive. One (4%) 
participants was unclear about the type of MS they had.  
For the continuous data of age, time since MS diagnosis and level of 
disability as measured by GNDS score means and standard deviations 
were calculated. The characteristics of the sample are summarised in 
the table below (table 12).  
Table 12 
Descriptive statistics for continuous data 
Variable Mean Standard 
Deviation 
Range 
Age of participant 
 
49.25 9.65 33-67 
Years since MS  
Diagnosis 
 
12.13 7.50 2-34 
GNDS Score 17.92 9.23 3 - 38 
 
3.3 Measures 
3.3.1 Exploring the distribution of scores. Statistical tests 
assume that the distribution of data is normal (Pallant, 2006). Therefore, 
a number of tests were conducted to ascertain if the data was normally 
distributed and this assumption was not violated. The three assessment 
measures of BAI, BDI-II and HADS were tested. Initially, the distribution 
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of the data was assessed visually through a histogram (see figures ±
three to six).  
 
Figure three: Histogram for total scores on BAI 
 
Figure four: Histogram for total scores on BDI-II 
6050403020100
12
10
8
6
4
2
0
Fr
eq
ue
n
cy
6050403020100
12
10
8
6
4
2
0
Fr
eq
ue
n
cy
Std. D
Histogram
Page 86 of 195 
 
 
Figure five: Histogram for total scores on HADS ± anxiety 
 
Figure six: Histogram for total scores on HADS - depression 
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The following criteria were used to assess if the data was normally 
distributed (adapted from Hinton, Brownlow, McMurray & Cozens, 
2004): 
 The histogram should be bell shaped 
 The tails should meet the x axis at infinity 
 The distribution of scores should be symmetrical about the mean 
Using these criteria, all the measures were found to be non-normally 
distributed. 
To assess the distribution using a more objective measure the 
skewness and kurtosis of the scores was computed. If the data is 
normally distributed then the skewness and kurtosis values should be 0, 
the further away from this they are the less likely the data is normally 
distributed (Field, 2005).  Field (2005) suggests that skewness and 
kurtosis are more informative if converted into a z score, this was done 
by subtracting the mean of the distribution and dividing it by the 
standard deviation of the distribution. A z score outside of ±1.96 is 
considered to be significantly outside of a normal distribution (p<0.5, 
Field, 2005). Finally the Shapiro-Wilk test was conducted as advised by 
Pallant (2006), a non significant score indicates the data is distributed 
normally. Table 13 provides a summary of the tests of normality 
conducted on the data. 
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Table 13 
Tests of normal distribution 
Measure Skewness Z 
Skewness 
Kurtosis Z  
Kurtosis 
Shapiro-
Wilk Test 
P value for 
Shaprio-Wilk 
Test 
BAI 1.69 3.57 3.02 3.29 .84 .001 
BDI-II 0.76 1.61 -0.21 - 0.23 .90 .019 
HADS - 
anxiety 
0.32 0.68 -1.19 -1.30 .92 .046 
HADS - 
depression 
0.19 0.40 -1.51 -1.64 .90 .018 
  
Following each of these tests being conducted the overall conclusion 
can be made that the scores on the BAI, BDI and HADS did not meet 
the assumptions of a normal distribution within this sample. Therefore, 
any tests being conducted would be non-parametric (Pallant, 2006). 
 3.3.2 Descriptive statistics of measures being assessed. 
Each of the participants completed a full set of the measures being 
assessed by the current study. Of the 21 participants included in the 
study nine (43%) were diagnosed as likely to have depression by the 
SCAN interview and eight (33%) were diagnosed as likely to have 
anxiety. The scores from the measures are summarised in table 14, as 
measures were found to be non-normally distributed the median and 
inter-quartile range are shown. 
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Table 14 
Participant scores on measures being assessed. 
Assessment   
Sample size 
(n) 
Inter-quartile 
Range  
(25% - 75%) 
Median 
BAI 24 6 ± 20 11.00 
BDI-II 24 5 ± 29 11.50 
HADS ± anxiety 24 1 ± 12 6.50 
HADS ± depression 24 1 ± 13 7.50 
BAI Repeat 17 3 ± 14 7.00 
BDI-II Repeat 17 3 ± 23 7.00 
HADS-anxiety Repeat 17 2 ± 9 2.00 
HADS-depression Repeat  17 2 ± 8     2.00 
 
*NB: Due to the pair wise deletion of missing data there was a smaller 
sample size for participants who completed the repeated measure3.3.3  
Kappa coefficients using advised cut offs. To compare the level of 
agreement with the advised cut off scores for the measures and the 
diagnosis provided by the SCAN interview a kappa analysis was 
conducted. The kappa calculation is preferable to the alternative of a 
SHUFHQWDJHDJUHHPHQWEHFDXVH³LWFRUUHFWVIRUWKHSUREDELOLW\WKDWUDWHUV
ZLOODJUHHGXHWRFKDQFHDORQH´/HHFK%DUUHWW	0RUJDQ7KH
output of the calculation gives a level of agreement in terms of a 
&RKHQ¶V .DSSD FRHIILFLHQW EHWZHHQ ]HUR DQG RQH WKH OHYHO RI
agreement between measures are labelled according to their strength 
(see table 15). 
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Table 15 
Strength of Kappa coefficient (adapted from Pallant, 2006) 
Kappa coefficient Level of agreement 
0 ± 0.4 Poor ± no better than chance 
0.5 ± 0.6 Moderate 
0.7  Good 
0.8 ± 0.9  Very good 
1 Perfect 
 
The results of the kappa analysis are shown in table 16. The BDI-II and 
both of the HADS subscales demonstrated statistically significant 
moderate to very good agreement with the diagnosis given by the 
SCAN. The BAI demonstrated non-significant poor agreement. 
Table 16 
Strength of kappa coefficient of measures in comparison with SCAN 
Measure Cases in meeting 
criteria for mood 
disorders in sample 
(n) 
Precentage Kappa 
coefficient  
BDI-II 9 43 0.81* 
BAI 11 52 0.34 
HADS-anxiety 9 43 0.70* 
HADS ± 
depression 
9 43 0.61* 
SCAN - 
depression 
9 43 - 
SCAN ± anxiety 8 38 - 
* Statistically significant (p<.05) 
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3.4 ROC analysis 
A ROC curve analysis is a commonly used tool for assessing the 
performance of individual measures in making accurate assessments of 
GLDJQRVLV=RX2¶0DOOH\	0DXUL,QWKHFXUUHQWVWXG\WKH52&
curve analysis was used to assess if the BDI, BAI and HADS correctly 
identified participants with MS who were experiencing depression or 
anxiety (as measured by the SCAN).  
A ROC curve plots sensitivity and specificity over a range of values. For 
tests examined in the present study, specificity is the probability that the 
test correctly classifies a person without depression and/or anxiety as 
negative (Fletcher & Fletcher, 2005). Sensitivity is the probability that 
the test correctly classifies a person with depression and/or anxiety as 
positive (Fletcher & Fletcher, 2005). The measures assessed in the 
current study have a continuous scale; this allows the cut off scores to 
be altered. Different cut off scores have different levels of sensitivity and 
specificity (e.g. Honarmand & Feinstein, 2009).   
In making the choice for an optimum cut off score for a measure a 
balance needs to be made between sensitivity and specificity. If the 
threshold is strict there are fewer false positives but an increased 
chance of failing to identify true instances of the construct of interest 
(Swets, Dawes & Monahan, 2000), in the current study the constructs of 
interest are depression and anxiety. It the threshold is more lenient  it 
will be likely identify there are more true positives but also produce 
more false positives (Swets et al., 2000). Although a perfect measure 
would have 100% sensitivity and 100% specificity this is rarely found in 
practice (Linden, 2006). The standards used in the current study reflect 
those used in previous research. Previous studies have considered 
measures with high specificity (>80%) and adequate sensitivity (>60%) 
to be acceptable (e.g. Eack et al., 2008; Sprinkle et al., 2002). 
The ROC curve plots sensitivity on the y axis against 1-specificity on 
the x axis for different scores on the measure. A 45o diagonal line 
drawn on the ROC curve corresponds to random chance (connecting 
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0,0 to 0,1). The gold standard diagnosis is represented as the straight 
lines forming the upper-left corner of the graph (connecting 0,0 to 0,1 
and 0,1 to 1,1; Linden, 2006). The measure being assessed is 
represented as curve between these two lines, the closer this line is to 
the gold standard the more accurate the classification from the measure 
(Swets et al., 2000). If the line is below the diagonal line then the 
performance on this measure is worse than chance. 
The area under the curve (AUC) provides a summary of the diagnostic 
accuracy of the measure (Zou et al., 2007). If the ROC curve 
corresponds to random chance then AUC=0.5, if it is perfect accuracy 
then AUC = 1. The closer the AUC is to 1, the more accurate the 
measure is (Zou et al., 2007). For measures to be used as screening 
tools, as was advocated in the aim of this study an AUC of.8 is thought 
to be acceptable.  
3.4.1 Contingencies Once the optimal cut off score for a 
measure was identified the new cut off score was transformed within 
SPSS.  Any scores below the new cut off score on the measure are 
assigned a value of 0 and any scores equal or above the new cut off 
score are assigned a value of 1. A two-by-two contingency table was 
used to represent the outcomes with the new cut off score (Fawcett, 
2006; see table 17).  
The data in the contingency table was used to determine the false 
positive rate, true positive rate, sensitivity and specificity for the new cut 
off using the metrics provided in table 18. The metrics also allowed for 
the positive predictive values (PPV) and negative predictive values 
(NPV) to be calculated, these allow the probability of the measures 
giving the correct diagnosis in the population being tested. The PPV is 
the proportion of individuals who are assessed as having depression or 
anxiety by the measure that actually have them (Chatburn, 2009). The 
NPV is the proportion of individuals who are assessed as not having 
depression or anxiety by the measure that do not have either 
(Chatburn, 2009).  
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Table 17 
Contingency table (adapted from Zou et al., 2007). 
 Gold standard (SCAN)  
Index Test 
(BAI/BDI/HADS) 
Positive for 
depression or 
anxiety 
Negative for 
depression or 
anxiety 
Total 
Positive for 
depression or 
anxiety 
A = true 
positives 
B = false 
positives 
A+B = test 
positives 
Negative for 
depression or 
anxiety 
C = false 
negatives 
D = true 
neagtives 
C + D = test 
negatives 
Total A+C = diseased 
B + D = non-
diseased 
A + B + C + D 
= total sample 
size 
 
Table 18 
 
Metrics for contingency table (adapted from Zou et al., 2007) 
 Metrics 
 
False positive rate 
 
B/ (B+D) 
False negative rate C/ (A+C) 
Sensitivity  A/ (A+C) x 100 
Specificity D/ (B + D) x 100 
Positive predictive Value(PPV) A/ (A + B) 
Negative Predictive Value (NPV) D / (C + D) 
Discriminant Ability Sensitivity + Specificity / 2 
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3.4.2 Analysis for BAI.  The ROC curve completed for the BAI 
demonstrates that it curves to the left but is not quite in the top left hand 
corner. The AUC is .81 (95% confidence interval = .62 -1), if rounded to 
one decimal place then the accepted level for this study of .8 is 
achieved.  
 
 
Figure seven: ROC curve for BAI scores 
 
The optimal cut off score for the BAI in people with MS in this sample 
was calculated using the co-ordinates of the ROC curve (see table 19). 
The optimum cut off score seems to be 9.5 as it identifies those who 
have anxiety as diagnosed by the SCAN interview, demonstrating good 
sensitivity (75%) and adequate specificity (61%). As a score of 9.5 
cannot be achieved with the BAI, the cut off will be viewed as those who 
score 10 or more will be viewed as anxious and those who score nine 
or less as not anxious. 
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Table 19 
 
Co-ordinates of ROC curve for BAI 
 
Positive if 
Less Than or 
Equal To 
Sensitivity Sensitivity 
(%) 
1-Specificity Specificity 
(%) 
.5 1.00 100 .92 8 
2 1.00 100 .85 15 
3.5 1.00 100 .77 23 
5 1.00 100 .62 38 
7 .86 86 .54 46 
9.5 .75 75 .39 61 
11.5 .63 63 .31 69 
12.5 .63 63 .23 77 
13.5 .63 63 .15 85 
16 .63 63 .07 93 
19 .50 50 .07 93 
22.5 .38 38 .07 93 
26.0 .38 38 0 100 
30.5 .25 25 0 100 
37.5 .14 14 0 100 
42 0 0 0 100 
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 Contingencies. As it was not appropriate to have a cut off score 
of 9.5 a score of more than ten was used to indicate anxiety, therefore 
sensitivity and specificity were calculated for a score of ten. The new 
optimum cut off score of 10 was redefined in SPSS into binary terms. 
Where a score of less than nine was given a value of zero and a score 
of more than or equal to 10 was given a value of one. A contingency 
table for these scores was then constructed (see table 18). 
 
Table 20 
Contingency table for BAI using 10 as a cut off 
 Gold standard (SCAN)  
Index Test - BAI Anxiety  No anxiety Total n 
Anxiety 6 5 11 
No anxiety 2 8 10 
Total n 8 13 21 
 
This table was then used to calculate the metrics (see table 16). The cut 
off score of 10 for the BAI identified 11 positive cases and 10 negative 
cases for possible anxiety. Using 10 as a cut off score the sensitivity of 
the BAI remains high (75%) as does the specificity (61%). The PPV of 
the BAI is55% (6/11=.55). The NPV of the BAI is 80% (8/10=.8). The 
discriminant validity of the test provides a useful summary and assumes 
that the SCAN is perfect (100%), for the BAI the discriminant ability is 
68% (75%+61% / 2 =.68). 
 
 Kappa coefficient. The kappa coefficient was calculated to 
assess the agreement between the BAI and SCAN diagnosis for anxiety 
when the new cut off score was used. The agreement level was poor 
(0.34, non-significant). 
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3.4.3 Analysis for BDI-II. The ROC curve completed for the 
BDI-II is good; it shows that the measure almost reaches the top left 
hand of the graph (figure eight). The AUC is also very high (.98, 
confidence interval .93-1.03) demonstrating the high accuracy of the 
measure. 
 
The co-ordinates of the curve were used to calculate an optimum cut off 
for the sample in the study. It appears that the optimum cut off for the 
BDI-II is 18 (table 21). This provides very high sensitivity (89%) and 
specificity (92%). 
 
 
Figure eight: ROC curve for BDI-II 
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Table 21 
Co-ordinates of ROC curve for BDI-II (extension of table 1 in journal 
article) 
Positive if 
Less Than or 
Equal To 
Sensitivity Sensitivity 
(%) 
1-Specificity Specificity 
(%) 
.5 1.00 100 .83 17 
1.5 1.00 100 .75 25 
3 1.00 100 .68 32 
4.5 1.00 100 .58 42 
5.5 1.00 100 .33 67 
6.5 1.00 100 .25 75 
7.5 1.00 100 .17 83 
10.5 .89 89 .17 83 
18 .89 89 .08 92 
24.5 .89 89 0 100 
26.5 .78 78 0 100 
28 .67 67 0 100 
30 .44 44 0 100 
33.5 .33 33 0 100 
37 .22 22 0 100 
40 .11 11 0 100 
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Contingencies. The new cut off score of 18 was then transformed 
in SPSS where all scores below 18 were given a value of zero and 
those equal to or above 18 were given a value of one. This allowed the 
contingencies to be calculated using the new cut off score (table 23). 
Table 22 
Contingency table for BDI-II 
 Gold standard (SCAN)  
Index Test 
BDI-II 
Positive for 
depression 
Negative for 
depression 
Total (n) 
Positive for 
depression 
8 1 9 
Negative for 
depression 
1 11 12 
Total (n) 9 12 21 
 
Using the new cut off score for depression the BDI-II identified nine 
participants with possible depression and 12 without. As was previously 
shown for this cut off score the sensitivity (89%) and specificity (92%) 
are high. The PPV is 88% (8/9 =.88) and the NPV is 92% (11/12-.92). 
The discriminant validity of the test is (89% + 92% / 2) 91% which is 
high.   
 
 Kappa coefficient. To assess the agreement between the BDI-II 
with the new cut off score and the SCAN a kappa coefficient was 
calculated. This showed very good agreement (0.81, p<.001). 
 
43 0 0 0 100 
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3.4.4 Analysis for HADS ± anxiety subscale. The ROC curve 
completed for the HADS-anxiety subscale shows that the measure 
almost reaches the top left hand of the graph (figure nine), confirmed by 
the high AUC (.96, confidence interval .89-1.04).  
 
The coordinates of the ROC curve were used to calculate the optimum 
cut off score for the HADS-anxiety subscale. The optimum score for this 
sample is 10 which demonstrates both high sensitivity (86%) and 
perfect specificity (100%; see table 24). 
 
Figure Nine: ROC curve for HADS anxiety subscale 
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Table 23 
 
Co-ordinates of ROC curve for HADS-anxiety subscale 
 
 Contingencies. The cut off score of 10 was used to transform the 
data in SPSS, where scores below 10 were given a value of zero and 
scores equal to or above 10 were given a value of one. This allowed a 
contingency table to be constructed (table 24). 
 
Positive if 
Less Than or 
Equal To 
Sensitivity Sensitivity 
(%) 
1-Specificity Specificity 
(%) 
.5 1.00 100 .69 31 
1.5 1.00 100 .46 54 
3 1.00 100 .39 61 
5 1.00 100 .31 69 
6.5 .86 86 .23 77 
7.5 .86 86 .15 85 
8.5 .86 86 .08 92 
10 .87 87 0 100 
11.5 .63 63 0 100 
12.5 .50 50 0 100 
14 .38 38 0 100 
16.5 .13 13 0 100 
19 0 0 0 100 
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Table 24 
Contingency table for HADS-anxiety subscale 
 Gold standard (SCAN)  
Index Test 
HADS- anxiety 
subscale 
Positive for 
anxiety 
Negative for 
anxiety 
Total (n) 
Positive for 
anxiety 
7 0 6 
Negative for 
anxiety 
1 13 15 
Total (n) 8 13 21 
 
The cut off score of 10 identified six positive cases for anxiety and 15 
negative cases. The table allowed for the matrices to be calculated. As 
stated previously with this cut off score the specificity was perfect 
(100%), the sensitivity was good at 87% (6/8=.87). The PPV was 100% 
(6/6=1) and NPV was high at 93% (13/14=.93). The discriminate validity 
for the test was very good at 94% (100% + 87% / 2 = .94).  
 
 Kappa coefficient. In order to measure the agreement between 
the HADS-anxiety subscale with a cut off of 10 and the SCAN diagnosis 
of anxiety kappa was calculated. A good agreement was found (.90, 
p<.01). 
 
3.4.5 Analysis for HADS ± depression subscale. The ROC 
curve which calculated for the HADS ± depression subscale was also 
good. The AUC was high (.96, confidence interval 88-1.03) 
demonstrating that overall the measure was quite accurate (see figure 
10). 
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The coordinates of the ROC curve were used to calculate the optimum 
cut off score, of 9.5. This demonstrated high sensitivity (78%) and 
higher specificity (92%; see table 23). When scoring the measure no 
decimal places are used, therefore the cut off score was rounded up to 
10. 
 
 
Figure 10: ROC curve for HADS depression subscale 
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Table 25 
 
Co-ordinates of ROC curve for HADS-depression (extension of table 3 
in journal article) 
 
 Contingencies. The optimum cut off score of 9.5 was rounded up 
to 10, as with the BAI (see section 3.4.2). The new cut off score of 10 
was transformed in SPSS so scores of nine or below were given a 
value of zero and scores of equal to or more than 10 were given a value 
Positive if 
Less Than or 
Equal To 
Sensitivity Sensitivity 
(%) 
1-Specificity Specificity 
(%) 
.5 1 100 .67 33 
1.5 1 100 .5 50 
2.5 1 100 .25 75 
4 1 100 .17 83 
6 .89 89 .17 83 
7.5 .78 78 .17 83 
9.5 .78 78 .08 92 
11.5 .68 68 0 100 
12.5 .56 63 0 100 
13.5 .44 50 0 100 
15 .22 25 0 100 
16.5 .11 13 0 100 
18 0 0 0 100 
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of one. This allowed a contingency table to be constructed and the 
accompanying matrices to be calculated (table 26). 
Table 26 
Contingency table for HADS-depression (adapted from Zou et al., 
2007). 
 Gold standard (SCAN)  
Index Test 
HADS-
depression 
Positive for 
depression 
Negative for 
depression 
Total 
Positive for 
depression 
7 1 8 
Negative for 
depression 
2 11 13 
Total 9 12 21 
 
Using the cut off score of 10 the HADS-depression scale identified 
seven cases with possible depression and 14 without. The sensitivity of 
the cut off score is good (78%) and the specificity is high (92%). The 
PPV value is 88% (7/8=.88) and the NPV value is 85% (11/13=.85). The 
discriminant validity of the measure is 85% (78% + 92% / 2).  
 Kappa coefficient. The agreement between the HADS-
depression subscale with a cut off of 10 and the SCAN diagnosis of 
depression is good (.70, p<.01). 
 
3.5 Reliability 
 
7KH UHOLDELOLW\ RI D PHDVXUH LV LWV¶ DELOLW\ WR FRQVLVWHQWO\ UHIOHFW WKH
construct being assessed (Field, 2005). Of concern in the current study 
is test retest reliability (see section 1.8.2 for further discussion of 
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reliability). If all other things are equal and the measure is reliable 
participants should achieve the same score at both time points (Field, 
2005). The two points of assessment of the measure are then 
compared using a correlation. Since the current study did not have 
normally distributed data a non-parametric test was needed and 
WKHUHIRUH 6SHDUPDQ¶V FRUUHODWLRQ FRHIILFLHQW ZDV FDOFXODWHG )LHOG
2005).  
 
For the current study the analysis of reliability involved a smaller sample 
size then the rest of the study (17 participants) as not all participants 
completed the repeated measures. As for the other measures missing 
data was excluded pair wise (see section 3.1.2). The results of the 
analysis are shown in table five (in journal article). The result of the 
Spearman correlation demonstrate statistically significant correlation in 
a positive direction, this suggests that the each of the measures 
assessed has good test re-test reliability (Field, 2005). 
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4. DISCUSSION 
Three of the four measures assessed were found to be valid to use with 
people with MS. The optimum cut off scores for these measures in the 
sample population was higher than was originally recommended when 
the scales were developed: the optimum cut off score for the BDI-II was 
18 (original cut off score in manual was 14) and the HADS anxiety and 
depression subscales were 10 (original cut off score recommended by 
developers was 8). The BAI was not found to be valid for use in people 
with MS due to its poor agreement with the gold standard SCAN 
interview. The implications of these results will be discussed in the 
context of previous and future research as well as their implications for 
clinical practice. A critical reflection of the study will be given before final 
conclusions are drawn. 
4.1 Placing findings in context of previous research 
4.1.1 BAI. The conclusion drawn from the results of this study 
imply that the cut off score for the BAI does not need to be adjusted 
when using it in people with MS. However, the poor agreement with the 
diagnosis provided by the clinical interview suggests that the BAI is not 
a valid measure to be used in this population.  
There has only been one previous study considering the use of the BAI 
in people with MS (Nicholl et al., 2001). This reflects the paucity of 
literature in MS regarding anxiety in comparison to depression (e.g. 
Honarmand & Feinstein, 2009). Nicholl et al. (2001) validated the BAI 
by comparing it to other measures of anxiety in people with MS and it 
was found to have similarly poor agreement between measures, 
consistent with findings of the current study. 
The BAI has been validated in people with comparable physical 
conditions to MS, for H[DPSOH SHRSOH ZLWK 3DUNLQVRQ¶V GLVHDVH. 
However concerns were expressed that the BAI overestimated the 
prevalence of anxiety LQ WKRVH ZLWK 3DUNLQVRQ¶V GLVHDVH (Higginson et 
al., 2001). Although the BAI did overestimate anxiety in this study (the 
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BAI suggested 48% of participants had anxiety as opposed to the 33% 
identified by the SCAN) due to the small sample size it is difficult to 
draw firm conclusions about this. The overestimation of anxiety in the 
sample of people with MS may be due to the nature of the measure 
which focuses on physical symptoms of anxiety rather than cognitive 
symptoms (Wilson et al., 2006). As a result there may be a strong bias 
particularly in terms of the confounding symptoms in the measure such 
DVµnumbness RUWLQJOLQJ¶which may be present in both MS and anxiety. 
This may also explain the poor agreement with the SCAN as the SCAN 
includes a range of symptoms of anxiety rather than exclusively 
physical symptoms. 
The test-retest reliability of the BAI demonstrated that it is a moderately 
reliable measure (6SHDUPDQ¶V U  .68). The results from the current 
study are in the lower end of the range found by previous studies (r 
=.67, Fydrich et al., 1992 to r=.83, DeBeurs et al., 1997). The paucity of 
literature reporting the test-retest reliability of the BAI could be due to 
the methodological design of many studies. To assess the test-retest 
reliability of a measure the measure needs to be completed a two time 
points. This may lead to logistic problems with recruitment. As was 
demonstrated in this study not all participants are willing to complete the 
repeated measure resulting in a small sample size. Additionally, some 
researchers may not ask participants to repeat measures due to ethical 
concerns about over assessing individuals. A further explanation for the 
lack of test-retest reliability reporting in the literature is that studies 
which do repeat measures (e.g. Moran and Mohr, 2005) may do so not 
to assess reliability of the measure but to detect change following an 
intervention, therefore although a retest is conducted it is not reported 
as reflecting the test-retest reliability of the measure. 
In summary the BAI was not found to be a valid measure for use in 
people with MS and is therefore not recommended for screening in 
people with MS. This reflects the small amount of previous studies 
which have attempted to validate the BAI in people with MS. 
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4.1.2 BDI-II. The results of the current study suggest that the 
BDI-II is a valid measure for use in people with MS when a higher cut 
off score of 18 is applied (rather than 14). This score demonstrates high 
sensitivity (89%) and specificity (92%), due to its good agreement with 
the SCAN interview (kappa = .81, p<.01). These results are in contrast 
with previous research which suggests both a lower cut off score (e.g. 
13; Sullivan et al., 1995) and poor agreement with other measures (e.g. 
kappa = .12 when compared to HADS; Nicholl et al., 2001).  
The higher cut off score in the current study in comparison to a previous 
study may reflect differences in the sample used.  Sullivan et al. (1995) 
used participants who had recently been diagnosed with MS. It may be 
that the differing recommendations for cut off scores are due to the 
impact of confounding symptoms. As MS is a progressive disease 
(Lezack et al., 2004) it may be assumed that those who are recently 
diagnosed have fewer symptoms than those who have had the disease 
diagnosed for some time. The higher cut off score in the current study 
for people with MS may reflect the greater potential number of 
confounding symptoms, such as fatigue (Mohr et al., 2003), in 
individuals where the MS has progressed further (see section 1.6) As a 
result a higher cut off score may be needed for measures assessing 
depression in people who have not recently been diagnosed with MS to 
reduce the number of false positives within a sample.  
An alternative explanation for the differing cut off scores between 
Sullivan et al. (1995) and the current study is the possible differential 
diagnoses given to those recently diagnosed with MS. The gold 
standard clinical interview to which the results were compared took into 
account recent life events, which would include the diagnosis of MS. 
Therefore, participants who have been recently diagnosed (i.e. in the 
study completed by Sullivan et al., 1995) may have been more likely to 
receive a diagnosis of adjustment disorder with depressed mood (DSM-
IV-TR, APA, 2000) rather than depression, to account for the impact of 
the diagnosis. The BDI-II would have then been adjusted to match the 
gold standard in order to validate it, potentially providing a lower cut off 
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score. In the current study people who had been recently diagnosed 
were excluded and so any potential difficulties in discriminating between 
depression and adjustment disorder were reduced. As a result, it is 
possible that more people were diagnosed with depression as a primary 
diagnosis (rather than adjustment disorder with depressed mood) and 
thus the cut off score of the BDI-II was raised to match this. Therefore 
the results from the current study may be a more accurate and useful 
reflection of the validity of the BDI-II in MS that that suggested by 
Sullivan et al. (1995). 
Unlike the current study, previous attempts at comparison between the 
BDI-II and other measures in people with MS have found poor 
agreement. Nicholl et al. (2001) compared to other measures of 
depression (e.g. HADS) but did not use a gold standard measure as 
was used in the current study. Nicholl et al. (2001) used the cut off 
score of eight for the HADS; however, the current study has 
demonstrated an optimum cut off score for the HADS measure is 10. 
The test-retest reliability of the BDI-II assessed in this study was very 
good (see section 3.5). This suggests that the construct of depression 
as measured by the BDI-II in people with MS is stable over time. The 
good reliability of the BDI-II found in the current study supports similar 
findings in previous studies: for example, Sprinkle et al. (2002) also 
found the BDI-II demonstrated a good test-retest reliability of in a 
sample of university counselling students 3HDUVRQ¶VU . There are 
limited studies which have assessed the test-retest reliability of the BDI-
II in comparison to those that have assessed the original BDI (Hagen, 
2007; Yin & Fan, 2000 completed a meta-analysis on the BDI and found 
good test-retest reliability, (3HDUVRQ¶VU  .69). In the development of the 
measure the test-retest reliability is reported as high (3HDUVRQ¶VU .93; 
Beck et al., 1996). However, this was computed using a small sample 
size (26 outpatients) and so there continues to be a lack of any large 
scale assessment of the test-retest reliability of the BDI-II. The paucity 
of literature considering the test-retest reliability of the BDI-II may reflect 
its development, as the measure was designed to both measure a 
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stable construct and be sensitive to change from treatment (Dozois & 
Covin, 2004). It has been shown with original BDI that scores decrease 
over time (e.g. Yin & Fan, 2000). The revised BDI-II covers a larger time 
period for participants to assess (how they feel currently in the BDI 
versus how they have felt over a two week period in the BDI-II) and as a 
result it may be expected that the BDI-II will demonstrate greater 
temporal stability (Dozois & Covin, 2004). However, further research is 
needed to test this hypothesis. 
In summary, although previous studies have suggested a lower cut off 
score when using the BDI-II in people with MS, these used different 
samples which lead to difficulties in making comparisons. Other 
previous studies have not compared the BDI-II to a gold standard. The 
BDI-II has been found to be both a reliable and valid measure for use in 
people with MS and therefore it is recommended that it is used as a 
screening measure. 
4.1.3 HADS. The results show both subscales of the HADS can 
be used as a valid measure of anxiety in people with MS with an 
increased cut off score of 10 for both subscales (rather than 8 which is 
recommend by the manual). 
The increased cut off score for the HADS is in contrast to that found in 
previous studies, such as the large scale validation project completed 
by Honarmand and Feinstein (2009). Given the importance of 
replication within scientific research (Reiss & Judd, 2000) this suggests 
concerns may be raised regarding generalising the conclusions from 
Honarmand and Feinstein (2009). Although the current study had a 
similar methodology it was completed on a Canadian population rather 
than in the UK where there is a different healthcare system and a lower 
prevalence rate of MS (e.g. Poppe et al., 2008).  
The higher cut off score suggested in the current study (10) rather than 
that recommended by Honarmand and Feinstein (2009; 8) may reflect 
the structure of the HADS measure. In its development it is suggested 
that a score of eight to 10 on the HADS indicates possible depression 
Page 112 of 195 
 
or anxiety and a score of 10 or more suggests probable depression or 
anxiety (Zigmond & Snaith, 1983). Therefore it may be that those with 
MS need to meet the higher end of the range to indicate possible 
depression or anxiety. In addition, the higher cut off score suggested for 
both anxiety and depression when using the HADS may reflect the 
confounding symptoms within the disorders, as discussed previously 
(see section 1.6). 
The test-retest reliability of the HADS in this study was good 
(6SHDUPDQ¶V U   .88 for depression subscale and r =.77 for anxiety 
subscale). This is similar to findings from previous studies (e.g. 
PearVRQ¶V U   .79-.80, Elliott, 1993) and studies considering 
international versions of the HADS (Herrmann, 1996). Although the test-
retest reliability of the HADS has been reported for people with MS, it 
has been reported for similar groups. For example, when used in 
SHRSOH ZLWK 3DUNLQVRQ¶V GLVHDVH WKH +$'6 KDV GHPRQVWUDWHG JRRG
test-retest reliability over a two week period (3HDUVRQ¶VU .88; Marinus, 
Leentijens, Visser, Stiggelbout & van Hilten, 2002) 
In summary, the HADS has been shown to be valid and reliable for use 
in people with MS. Although this study contrasts with  previous studies 
that have validated the HADS in people with MS, this may reflect subtle 
differences in the samples used. The slightly higher cut off score 
reflects the higher end of the range recommended by the original 
manual. 
           4.1.4. Prevalence of anxiety and depression.  The number of 
people with depression and anxiety found in this study (33-48% 
depending on the measure) reflected the prevalence rates in some 
previous studies (e.g. Smith & Young, 2000; Gelazzi et al., 2005) but 
not all (e.g. Barmer et al., 2008; Feinstein et al., 2002b). This highlights 
the wide variance in prevalence rates reported in studies as discussed 
previously. This could possibly reflect the difficulties in assessing these 
constructs in people with MS (e.g. confounding symptoms, see section 
1.6). 
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In the current study a difference in prevalence was found when using 
different measures, although this was interpreted as high in comparison 
to previous research (e.g. Nicholls et al., 2001). The range of variation 
was greater for anxiety (33-48%) then for depression (all 38%). 
However if the non-validated measure (BAI) is removed then the range 
is reduced (33-38%). The small differences between the measures may 
reflect the small sample size used in the current study.  
4.1.5. Participant characteristics. Despite the high numbers of 
participants invited to take part in the study, only a small number 
decided to participate (24%). In comparison to other research 
considering questionnaire data this uptake is low (e.g. 55% expected; 
Baruch, 1998). Recruitment is cited as the most challenging part of a 
study (Patel, Doku & Tennakoon, 2003), as was reflected in this study. 
The low recruitment rate is perhaps surprising given that participants 
were approached because they had previously agreed to be contacted 
regarding research in MS. It may have been that participants had 
already been recruited for a number of studies as the centre in which 
the study was based produces a high volume of research involving 
people with MS. The poor recruitment levels may also reflect the study 
design which involved the participants completing a number of steps. 
This resulted in a complex information sheet which may have deterred 
potential participants from opting in to the study. Finally the nature of 
the study may have deterred some participants. Those with depression 
may not have felt motivated to be involved, or poor health in potential 
participants may have adversely affected participation rates in this study 
(Patel et al., 2003). Despite the difficulties with recruitment there is no 
proven method of improving participant recruitment to research (e.g. 
Mapstone, Elbourne & Roberts, 2007). Possible ways to improve 
recruitment would be to offer participants an incentive or contacting 
potential participants by telephone rather than simply by letter. 
The representativeness of the sample in the current research is outlined 
in table 27. There is a higher incidence of depression and anxiety in 
females aged between 25 and 40 years (Piccinelli & Wilkinson, 2000; 
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Somers, Coldner, Waraich, & Hsu, 2006; Kessler et al., 2007). This is 
similar to the incidence of MS which is more prominent in females of a 
similar age (Sadovnick, 2009). Therefore the demographic information 
gathered as part of the current study demonstrates that it was a 
representative sample. 
Table 27 
Epidemiological Findings and Study Sample 
 Depression Anxiety MS Study Sample 
Age at 
onset 
25 ± 45 years 25 ± 53 years 20 ± 40 years 37 years (mean) 
Gender Female Female Female (3:1) Females (3:1) 
 
The gender difference in prevalence of anxiety and depression cannot 
be fully explained by the symptoms reported in the different genders 
(Piccinelli & Wilkinson, 2000), however the different symptoms reported 
in different genders may be relevant for the current study. When 
reporting depression, females report symptoms with appetite and sleep 
change, fatigue and somatic anxiety (Young, Scheftner, Fawcett, & 
Klerman,1990). It is these symptoms (according to conceptual map, see 
figure one) that closely relate to the symptoms of MS. Therefore, having 
a high proportion of females with a diagnosis of MS, describing 
symptoms of depression that closely relate to the symptoms of MS, may 
partially explain the higher prevalence rates of depression in MS. 
The type of MS in the sample is more complex. It is estimated that at 
diagnosis approximately 85% of people with MS are diagnosed as 
relapsing remitting, 50% of these will then go on to develop secondary 
progressive after some years and the remaining 15% are diagnosed 
with primary progressive MS at onset (Cook, 2005). Within the current 
sample, this was relatively similar with 17% of participants being 
diagnosed with primary progressive MS. Relapsing remitting MS was 
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the diagnosis in 58% of participants, a further 21% had secondary 
progressive MS which will have begun as relapsing remitting MS. 
Therefore, a total of 79% would have had a diagnosis of relapsing 
remitting MS at onset but only 36% have gone on to have a diagnosis of 
secondary progressive MS at the time the current study was conducted. 
It may be that some of the participants with relapsing remitting MS have 
yet to develop secondary progressive MS, or this has yet to be formally 
diagnosed for some participants (Cook, 2005).  
Furthermore, the age at which the symptoms of depression begin is the 
time of the emergence of gender differences in social roles (Wilhem, 
Parker & Hadzi-Pavlovic, 1997). To understand the impact this has, it is 
important to note that although MS is diagnosed at a mean age of 30 
years (Olek, 2005) as the diagnosis is a process of exclusion (Trojano & 
Paolicelli, 2001) it can take some time to achieve a diagnosis, which 
may explain the slightly later age of diagnosis within the current study 
(37 years). In addition, the similarity of age of diagnosis of multiple 
sclerosis, anxiety and depression (as summarised in table 28) may 
explain some of the increased co-morbidity within the disorders. The 
level of disability experienced by the participants was measured using 
the GNDS (mean score 17.92; range 3 ± 3DUWLFLSDQWV¶PHDQ OHYHO
of disability was slightly higher to that reported in previous studies (e.g. 
12.0, Stanton, Barnes & Sibler, 2006). The elevated level of disability 
may reflect both the propensity of people with MS to over-estimate their 
level of disability (Smith & Young, 2000) and difficulties in completing 
the GNDS. Although this tool was developed specifically for people with 
MS in reality it is a complex questionnaire to complete. A review of the 
completed questionnaires suggested that many participants appeared 
to have misunderstood the instructions and as such missed out items. 
As a result of this their scores were elevated as is suggested in the 
directions for scoring the questionnaires. Therefore the level the 
measures may not provide an accurate reflection of disability. One way 
to improve this in future research would be to provide clearer 
instructions for the measure or for a researcher to complete the 
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measure with the participant which would allow queries to be answered. 
Other demographic information gathered from participants suggested 
that it was a representative sample. For example the type of MS that 
participants reported was very similar to that reported in studies with 
much larger sample sizes considering people with MS (e.g. Confavreux 
& Vukusix, 2005).  
In summary, the similarities in the demographic characteristics of the 
sample in terms of disability and type of MS imply that it is 
representative of the wider population of people with MS and therefore 
gives further weight to the generalisability of the findings. 
4.2 Strengths and limitations 
The results of the study demonstrated that the HADS and BDI-II were 
valid for use in people with MS whereas the BAI was not. This section 
will consider the details of the study, examining the strengths and 
limitations of the methodology and design. 
         4.2.1 Strengths.  
         Methodology. As discussed previously (see section 1.8) there 
are a number of ways in which to validate measures. This study 
compared measures to a recognised gold standard which is seen as a 
particularly robust methodology to assess the criterion validity (e.g. 
Pattern et al., 2003). This was further strengthened by the use of a 
research associate who scored the measures allowing the researcher to 
remain blind to the scores when conducting the interviews, reducing 
interpretation bias. 
      Contributing to knowledge. The study adds to the wider body of 
knowledge regarding MS and mood disorders. As is discussed 
previously this is particularly important because of the paucity of 
research regarding anxiety in MS (e.g. Honarmand & Feistein, 2009). In 
adding to this knowledge base and providing valid measures for use in 
this population many of the problems outlined within the introduction are 
addressed. For example, by having valid measures of future research 
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can accurately assess the  prevalence of depression and anxiety in 
people with MS and further research can be conducted into finding the 
most effective interventions for this population. 
4.2.2 Limitations. 
 Recruitment and subsequent sample size. The sample size 
for the study was small, although it allowed enough power for the 
statistical tests to be meaningful. A larger sample size would have 
greater statistical power and thus greater confidence in results and 
generlaisabilty of the findings. The study will be continued once the 
current thesis is completed by a member of the research team and thus 
the sample size will be increased. It will be interesting to see if these 
impacts on the results presented in this thesis. 
 Measuring validity and reliability. Although the study did find 
that some of the measures assessed were both valid and reliable for 
use with an MS population, not all types of reliability and validity were 
considered. Therefore although it can be concluded that, for example, 
the BDI-II has good criterion validity, the construct validity for the 
measures assessed is not known for this population.  
 Difficulties with sensitivity and specificity. Although the 
specificity and sensitivity of the measures was very high, for the 
majority of these it was not 100%. As a result this means that there is 
still a possibility that people who are experiencing symptoms of 
depression and anxiety will not be picked up by the measures. This 
implies that any screening that is conducted using the measures that 
have been validated should be done with caution (for further discussion 
of the impact of screening see section 4.5). However, it must be noted 
that the sensitivity and specificity of the measures was similar to that 
found when assessed for other client groups (e.g. BDI-II in people with 
brain injury suggested sensitivity of 87% and specificity of 79%, 
Homaifar et al., 2009) 
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4.3 Recommendations for future research 
 4.3.1 Screening tools. The validation of the measures for 
depression continues the process of developing them for screening as 
recommended for all people with long term health conditions (NICE, 
2009). However this advice is in conflict with that given by the UK 
National Screening Committee (Albany, 2010). Anxiety was not 
recommended for screening by NICE (2009) and has not yet been 
considered by the National Screening Committee. The strict criteria of 
the NSC (NSC, 2003) mean that although screening can improve the 
detection of a disorder such as depression(Allaby, 2010) it also needs 
to improve the outcome (see section 4.5for discussion of screening). 
Future research needs to be conducted assessing if the measures 
which have been validated in people with MS impact on the outcomes 
when employed as screening tools. 
  4.3.2 Replications. This study found that three of the measures 
were valid for use in people with MS. The cut off scores identified 
contrasted with previous studies that had used a similar methodology 
(e.g. Honarmand & Feinstein, 2009). This contrast and variation 
highlights the importance of replication within scientific research (Reiss 
& Judd, 2000) which although often recommended is rarely conducted 
(Reis & Judd, 2000). Therefore it is recommended that future research 
is conducted to repeat the study to assess reliability of findings and 
draw conclusions together.  
4.4 Clinical implications 
 4.4.1 Access to treatment. It has been shown that both 
depression and anxiety within MS are treatable disorders (e.g. Mohr & 
Goodkin, 1999) and the impact of treatment of depression or anxiety in 
SHRSOH ZLWK 06  RQ WKH SHUVRQ¶V TXDOLW\ RI OLIH LV VLJQLILFDQW HJ
Lobentanz et al., 2004). Despite this access to treatment for depression 
or anxiety is very poor (e.g. Feinstein, 2002). If participants with MS 
were given the validated measures by healthcare professionals and 
researchers it is hoped that access to treatment would be improved. 
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However, some authors caution against using measures for screening 
tools that have not been designed for the purpose (e.g. BDI-II; Hagen, 
2007) despite the precedent that has been set for using the measures 
this way (e.g. Lasa, Ayuso-Mateos, Vazquez-Barquero, Diez-Manrique 
& Dowrick, 2000; Leyfer et al., 2006). Further cause for caution and 
clinical judgement to be used in conjunction with the measures is the 
potential misidentification of individuals due to their imperfect levels of 
sensitivity and specificity (see section 4.2.2). 
 4.4.2 Assessment of prevalence. It is hoped that the 
prevalence of depression and anxiety within this population can be 
correctly assessed through the identification of appropriate and valid 
measures contributed by this study. In doing so, commissioners and 
others can potentially target research and resources if the prevalence of 
depression and anxiety in MS is found to be particularly high. Although 
this particular study may not provide an accurate estimate of prevalence 
due to its small sample size, it allows future studies to do so using 
measures that have been validated for the population. 
 4.4.3 Further research. Previous research using the measures 
validated in the current study has utilised a range of cut off scores even 
when research has been completed by the same authors. For example, 
Feinstein et al. (1999) used the HADS with a cut off score of 11 but 
Korostil & Feinstein (2007) used the same measure with a cut off score 
of 10 with no justification in either paper for this choice. Therefore, in 
having the measures validated for use in people with MS the measures 
can be used in research employing the same valid cut off scores, and 
thus comparisons can be made between different studies more easily 
and conclusions generalised. This would allow specific research to be 
conducted in areas such as comparing treatments for depression and 
anxiety in people with MS and factors influencing the relationships 
between depression, anxiety and MS such as disability (Tsivgoulis et 
al., 2007) and social support (Beckner et al., 2010). 
Page 120 of 195 
 
Further research has already begun with a pilot study linked to the 
current study. Participants from the current study were asked to 
participate in a study considering the MRI scans depression in people 
with MS (R, Dineen, personal communication, 9th August 2010). 
4.5 Critical reflection  
This study aimed to validate mood measures in the MS population. 
Positivism aims to build up knowledge of phenomena through 
systematic observation, and then often uses logic to draw inferences or 
theories about phenomena from these observations.  In order to work it 
assumes phenomena are held stable, so that they can be observed 
systematically, and that observations are objective and free from bias 
(Hesse-Biber & Leayy, 2010).  The procedures of psychological science 
have been developed in order to achieve these requirements of holding 
phenomena stable, so they can be observed (Gliner & Morgan, 2000). 
Thus, in the current study the constructs of anxiety and depression are 
assumed to be stable and there are laws governing them, therefore 
providing appropriate procedures are followed the results of the study 
can be generalised (Gilner & Morgan, 2000). 
A critical realist epistemological position is sometimes contrasted with a 
positivist position in quantitative research (e.g. Garner, Wagner & 
Kawulich, 2009), possibly because the two positions share many 
characteristics. Critical realism assumes that knowledge about 
phenomena can be generated by observation and making true 
observations can be technically very difficult (Sayer, 2000). In contrast 
to positivism, it is sceptical about whether objective observations can 
ever be made, even if scientific procedure is followed. It is also less 
sure that phenomena, especially social phenomena can be stable 
enough to be observed (Parker, 1999, 2000). 
These two positions lead to different assumptions being made in the 
current study. The positivist position suggests that the constructs of 
anxiety and depression are valid and can be reliably measured by the 
SCAN diagnostic interview. The critical realist approach would state that 
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the constructs are valid but cannot be reliably measured by the SCAN 
alone.  
From a positivist stance, the researcher aims to be independent of what 
is being researched; they are objective observers (Hesse-Biber & 
Leavy, 2010). To achieve this, in the current study, attempts have been 
made to control possible observer bias. For example, the researcher 
was blind to WKHSDUWLFLSDQWV¶UHVSRQVHVRQmeasures when conducting 
the SCAN interviews. In addition, the training for the SCAN interview 
included tests of inter-rater reliability. Thus, it can be assumed, from the 
positivist position, that should another trained individual complete the 
interviews undertaken by the researcher, they would achieve similar 
results. In contrast, the critical realist position would suggest that the 
inter-rater reliability went some way to demonstrate that the SCAN was 
successful in measuring the truth of the constructs of depression and 
anxiety+RZHYHUGXHWRLWV¶OLPLWDWLRQVWKH truth of these constructs is 
still unknown. 
As the current study wishes to find the underlying truth and knowledge it 
is important that the debate over accessing the truth is resolved. The 
critical realist position poses an interesting argument but does not allow 
for the study to draw conclusions that can be generalised. For this to 
occur, a positivist epistemology was used and as a result classical test 
theory was applied. This allows the results of the study to be 
generalised to the population from which the sample was taken (Kline, 
2000). In the current study, the results can be applied to individuals with 
a diagnosis of MS. 
The positivist epistemology of the study assumes the evidence for 
anxiety and depression is interpreted as true descriptions of the 
construct; there is empirical evidence demonstrating that they are both 
stable and measurable (using a structured scientific interview). The 
methodology then allowed different assessment measures of anxiety 
and depression to be assessed for validity against the structured 
interview. Furthermore, a robust methodology allows the results of the 
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study to be generalised to the wider population. However, within the 
positivist epistemology of the study, some difficulties need to be 
acknowledged regarding the measurements used; firstly the 
imperfection of the gold standard interview in mental health and 
secondly the use of self report measures. 
The assumption is made that the constructs of depression and anxiety 
were valid and could be reliably measured using the SCAN interview as 
a gold standard. However, it is possible that the gold standard is 
imperfect (Zou et al., 2007). Although the SCAN has been shown to be 
reliable (Rijiners et al., 2000), its validity in comparison to gold 
standards utilised in physical health is very poor (e.g. glucose test for 
diabetes; International Expert Committe, 2009). It addition, its validity in 
comparison to alternative gold standards measuring anxiety and 
depression is also poor (Brugha et al., 2001).  
The study has also utilised self report measures, which are cited as 
being the ³PRVW ZLGHO\ XVHG PHDVXUHPHQW WRROV LQ SV\FKRORJ\ >DQG@
also among the moVW FULWLFLVHG´ +DIIHO 	 +RZDUG, 2010 pp.181). An 
inherent difficulty with self report from a positivist position is the 
assumption that they suggest an accurate reporting of an underlying 
truth. When considering internal states measurement becomes difficult 
as there are no external references and it is assumed that the truth is a 
fixed point, that is, if someone else interpreted the same data at the 
same time they would reach the same conclusion.  
However, individuals completing self report measures are susceptible to 
demand characteristics and potential bias as they are unable to 
accurately observe their own cognitive processes (Nisbett & Wilson, 
1977), a problem not found in behavioural or biological measures 
(Haffel & Howard, 2010). Psychometric theory has attempted to 
address these inherent difficulties within measurement. Key debates 
such as classical test theory and item response theory are discussed 
elsewhere (see section 1.8).  
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When considering the validity of self report measures there are few 
studies where both self and clinician ratings are compared to a third 
source or a biological measure, for example a MRI scan (Joiner et al., 
2005). Instead studies may measure both self-report ratings and 
clinician ratings for the same difficulty in the same participant. Some 
individual studies have reported agreement between self-report and 
clinician ratings (e.g. Kaplan et al., 1994; Hopko et al., 2000) but this 
finding was not replicated in a recent meta-analysis (Cuijpers, Hofmann 
& Andersson, 2010). 
Taking this literature into account it may be possible that using a self 
report measure led people to overestimate their difficulties, something 
which is not acknowledged within a positivist epistemology. This has 
been shown to be the case for people with MS (e.g. Smith & Young, 
2000), depression (Corruble, Legrand, Zvenigorowski, Duret & Guelfi, 
1999) and anxiety (e.g. Higginson et al., 2001). It is hoped these effects 
are counterbalanced by the newly suggested cut off scores for the 
measures. 
Within this study, the positivist position would also imply that the results 
can be generalised (Gliner & Morgan, 2000). Therefore, since the BDI-
II, BAI and HADS have been validated they can then be used as 
screening tools for depression and anxiety in those with a diagnosis of 
MS, and so the aim of the study was achieved. However, if screening 
tools are to be used then this should not be done without 
acknowledgement of the potential ethical issues that may arise.  
Much of the criticism of screening measures lies in the danger of 
identifying false positives (Walker et al., 2007). These concerns 
demonstrate the stigma that continues to surround mental health 
difficulties (Gilbody, Sheldon & Wessely, 2009). The impact of 
misidentifying participants and suggesting someone has a diagnosis of 
depression and/or anxiety may be more pertinent to individuals with 
MS. Qualitative studies have shown that communication and 
information given to people when receiving their MS diagnosis is poor 
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(e.g. Solari et al., 2007; see Solari et al., 2010 for an extension of this 
study into developing a questionnaire). For people with MS who may 
have already received a diagnosis with little support, receiving more 
diagnoses via screening measures may be inappropriate.  
Systematic reviews have been conducted in an attempt to objectively 
assess the value of screening measures; however, these have resulted 
in conflicting conclusions. For example when considering screening for 
depression in primary care Pignone et al. (2002) found that screening 
can lead to improved patient outcomes but Gilbody, House and Sheldon 
(2005) found screening had little impact on the management or 
outcomes of depression. More recent systematic reviews have provided 
more detail, for example 2¶&RQQRU:KLWORFN %HLO DQG *D\QHV 
concluded from their rHYLHZ WKDW VFUHHQLQJ SURJUDPPHV¶ impact on 
improvement of depression outcomes was moderated by the 
involvement of staff.  
A further consideration is the uptake of screening programmes. 
Although rarely discussed explicitly in the literature, uptakes for 
screening of mental health problems in healthcare settings are low (30-
60%; Gilbody et al., 2005). It may be that patients do not want to be 
screened. This has been shown in a qualitative study completed by 
Wittampf et al. (2008) who reported that some patients found screening 
programmes aversive, particularly if they had acquired a diagnosis of 
depression through the screening programme they had previously 
undisclosed. 
Screening for depression improves patient outcomes in people with 
physical illness only when accompanied by effective treatment and 
follow up. Implementation of wide spread depression screening in 
medically ill patients would be a costly process that will not benefit 
patients if sufficient resources are not made available to ensure parity, 
accessibility, appropriate delivery and correct monitoring of treatment 
(Evans et al. 2005). Therefore, any screening should be conducted with 
Page 125 of 195 
 
caution and as stated by Eaton et al. (2000) should utilise the support of 
well trained and knowledgeable staff. 
 
4.6 Conclusions 
The study found that the BDI-II and the HADS were valid measures to 
use with people with MS. The strength of the study lies in the clinical 
implications of this. By having valid measures for the assessment of 
depression and anxiety it is hoped that difficulties shown in the literature 
can be addressed. Those with MS can be screened for depression and 
anxiety using the measures (in conjunction with clinical judgment) and 
thus may have greater access to treatment. Valid measures will allow 
the accurate assessment of prevalence of depression and anxiety in 
MS which in turn may help towards commissioning decisions based 
around the targeting of resources. Finally, valid measures will allow 
further research to be conducted on the effectiveness of different 
treatments for depression and anxiety in people with MS. It is hoped 
that this will improve the quality of life for people with MS experiencing 
depression and/or anxiety. 
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protocol and supporting documentation as revised, subject to the conditions 
specified below. 
Ethical review of research sites 
The favourable opinion applies to all NHS sites taking part in the study, subject 
to management permission being obtained from the NHS/HSC R&D office 
ƉƌŝŽƌƚŽƚŚĞƐƚĂƌƚŽĨƚŚĞƐƚƵĚǇ ?ƐĞĞ ?ŽŶĚŝƚŝŽŶƐŽĨƚŚĞĨĂǀŽƵƌĂďůĞŽƉŝŶŝŽŶ ?
below). 
Conditions of the favourable opinion 
The favourable opinion is subject to the following conditions being met prior 
to the start of the study. 
Management permission or approval must be obtained from each host 
organisation prior to the start of the study at the site concerned. 
)RU1+6UHVHDUFKVLWHVRQO\PDQDJHPHQWSHUPLVVLRQIRUUHVHDUFK³5	'
DSSURYDO´VKRXOGEHREWDLQHGIURm the relevant care organisation(s) in 
accordance with NHS research governance arrangements.  Guidance on 
applying for NHS permission for research is available in the Integrated 
Research Application System or at http://www.rdforum.nhs.uk.   
 
Where the only involvement of the NHS organisation is as a Participant 
Identification Centre, management permission for research is not required but 
the R&D office should be notified of the study. Guidance should be sought from 
the R&D office where necessary. 
 
Sponsors are not required to notify the Committee of approvals from host 
organisations. 
It is the responsibility of the sponsor to ensure that all the conditions 
are complied with before the start of the study or its initiation at a 
particular site (as applicable). 
 
Approved documents 
The final list of documents reviewed and approved by the Committee is as 
follows: 
Document    Version    Date      
Covering Letter    09 October 2009    
REC application  22577/67171/1/845  12 October 2009    
Protocol  1  23 September   
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2009  
Evidence of insurance or indemnity    28 July 2009    
Letter from Sponsor    06 October 2009    
Investigator CV  Chief Investigator 04 May 2009    
Participant Consent Form: opt-in slip  2  01 October 2009    
Referees or other scientific critique report         
Questionnaire: Demographic Information  1  01 April 2009    
Covering Letter  2  01 August 2009    
Investigator CV  Student  08 October 2009    
Questionnaire: Hospital Anxiety and Depression 
Scale  
       
Questionnaire: BAI         
Investigator CV  Supervisor 11 September 
2009  
  
Participant Information Sheet  5  01 November 
2009  
  
Participant Consent Form  5  01 November 
2009  
  
Consultant Letter  1  01 November 
2009  
  
Guy's Neurological Disability Scale         
Response to Request for Further Information    24 November 
2009  
  
 
Statement of compliance 
The Committee is constituted in accordance with the Governance 
Arrangements for Research Ethics Committees (July 2001) and complies fully 
with the Standard Operating Procedures for Research Ethics Committees in 
the UK. 
After ethical review 
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Now that you have completed the application process please visit the 
National Research Ethics Service website > After Review 
You are invited to give your view of the service that you have received from 
the National Research Ethics Service and the application procedure.  If you 
wish to make your views known please use the feedback form available on the 
website. 
The attached document  ?ĨƚĞƌĞƚŚŝĐĂůƌĞǀŝĞǁ ? ŐƵŝĚĂŶĐĞĨŽƌƌĞƐĞĂƌĐŚĞƌƐ ? gives 
detailed guidance on reporting requirements for studies with a favourable 
opinion, including: 
 Notifying substantial amendments 
 Adding new sites and investigators 
 Progress and safety reports 
 Notifying the end of the study 
The NRES website also provides guidance on these topics, which is updated in 
the light of changes in reporting requirements or procedures. 
We would also like to inform you that we consult regularly with stakeholders 
to improve our service. If you would like to join our Reference Group please 
email referencegroup@nres.npsa.nhs.uk.  
 
09/H0406/112 Please quote this number on all correspondence 
 
Yours sincerely 
 
 
 
Dr Carl Edwards / Miss Jeannie D McKie 
Chair / Committee Coordinator 
 
Email: jeannie.mckie@nottspct.nhs.uk 
 
Enclosures:  ?ĨƚĞƌĞƚŚŝĐĂůƌĞǀŝĞǁ ? guidance for ƌĞƐĞĂƌĐŚĞƌƐ ? SL- AR2 for other 
studies 
Copy to: Paul Cartledge, Reserach Innovation Services 
R&D office for NHS care organisation at lead site 
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APPENDIX C: Confirmation of ethical approval from NHS trust 
research and development department 
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APPENDIX E: Cover letter of information pack sent to participants 
Tessa Hopkins 
Institute for Work, Health and Organisations 
Jubilee Campus 
Wollaton Road 
University of Nottingham 
NG8 1BB 
Telephone: 0115 8467523 
To Whom It May Concern, 
RE: Study to assess the appropriateness of measures of mood 
within a Multiple Sclerosis patients. 
Thank you for enquiring about the above study. Please find enclosed: 
 An information sheet for you to read to find out more about the 
study and allow you to decide if you want to take part 
 A consent form for you to look at if you are willing to take part in 
the interview 
 An opt-in slip for the interview and to receive a summary of the 
results once the study is complete 
 Five Questionnaires labelled: BDI, BAI, Hospital Anxiety and 
'HSUHVVLRQ 6FDOH 'HPRJUDSKLF ,QIRUPDWLRQ DQG *X\¶V
Neurological and Disability Scale. 
 A stamped addressed envelope 
Please read through the information sheet. If having read the 
information sheet you decide you do not wish to take part in the study 
then please return the contents of this pack to the above address. If you 
decide you do wish to take part then please complete the 
questionnaires before returning them in the stamped addressed 
envelope. By completing the questionnaires you are implying that you 
consent to the information you provide in the questionnaires being used 
in the study. 
If you are willing to take part in an interview as well as complete the 
TXHVWLRQQDLUHVSOHDVHLQGLFDWHWKLVRQµRSW-LQ¶VOLSDQGUHWXUQLWZLWKWKH
completed questionnaires. You will be contacted to arrange a time and 
place to complete the interview or to inform you that no interview is 
necessary. Consent for the interview will be discussed with you prior to 
the interview taking place. 
If you have questions or concerns please contact using the details 
above. Thank you for your time, 
Tessa Hopkins (study co-ordinator)
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APPENDIX F: Consent Form 
CONSENT FORM 
(Draft Version 3 / Final version 1.0: September) 
Title of Study: The validation of mood measures for use with 
patients with Multiple Sclerosis 
REC ref:   
Name of Researcher: Tessa Hopkins      
Name of Participant: 
1. I confirm that I have read and understand the information 
sheet version number 3 dated September 2009 for the 
above study and have had the opportunity to ask 
questions. 
2. I understand that my participation is voluntary and that I 
am free to withdraw at any time, without giving any 
reason, and without my medical care or legal rights being 
affected. I understand that should I withdraw then the 
information collected so far cannot be erased and that this 
information may still be used in the project analysis. 
3. I understand that relevant sections of my medical notes 
and data collected in the study may be looked at by 
authorised individuals from the University of Nottingham 
where it is relevant to my taking part in this study. I give 
permission for these individuals to have access to these 
records and to collect, store, analyse and publish 
information obtained from my participation in this study. I 
understand that my personal details will be kept 
confidential. 
4.  I understand that the interview will be recorded and that 
anonymous direct  quotes from the interview may be used 
in the study reports.  
5. I agree to take part in the above study. 
 
__________________ ______________    
 ____________________ 
Please initial box 
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Name of Participant   Date          Signature 
 
________________________ ______________    
 ____________________ 
 Name of Person taking consent Date          Signature 
 (Study Co-ordinator) 
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APPENDIX G: Opt in slip 
 
 
The validation of mood measures for use with patients with 
Multiple Sclerosis 
OPT-IN SLIP 
If you are willing to take part in an interview or you would like to receive a 
summary of the results when the research is complete than please provide 
your contact details below. Your contact details will be kept confidential and 
secure at the University of Nottingham and will be destroyed once they are no 
longer needed.  
Name:  __________________________________________________ 
Address: __________________________________________________ 
  __________________________________________________ 
  __________________________________________________ 
Contact Number: ______________________________ 
Please tick to indicate whether you are willing to take part in an interview or 
if you would like a summary of the results. 
  I am willing to take part in an interview 
  I would like to be sent a summary of the results once the 
research   is complete 
Signed______________________________   Date__________ 
 
Please return with questionnaires in stamped envelope provided. 
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APPENDIX H: Information sheet sent to participants 
 
 
 
Participant Information Sheet 
Study to assess the appropriateness of measures of mood within a 
Multiple Sclerosis patients. 
 
I would like to invite you to take part in a research study. Before you 
decide you need to understand why the research is being done and 
what it would involve for you. Please take the time to read the following 
information carefully. Talk to others about the study if you wish. 
Please contact me if there is anything that is not clear or if you would 
like more information. Take the time to decide whether or not you wish 
to take part. 
What is the purpose of the study? 
The study is looking at how anxiety and depression are assessed using 
questionnaires for people who have a diagnosis of multiple sclerosis. 
7KHVWXG\¶VSXUSRVH LV WRHQVXre the questionnaire assessments used 
to assess anxiety and depression are appropriate to be used with 
people with multiple sclerosis. The completed research will go on to 
form part of a qualification for a Doctorate in Clinical Psychology. 
Why have I been invited? 
You have been invited because I am interested in people with a 
diagnosis of multiple sclerosis, some with anxiety and/or depression 
and some without. In total 18 people will be recruited to take part in the 
study. 
Do I have to take part? 
It is up to you to decide. The study is described in this information 
sheet. We will then ask you to sign a consent form to show you have 
agreed to take part. You are free to withdraw at any time, without giving 
a reason. This would not affect the standard of any care you receive. 
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What will happen to me if I take part? 
You will be involved in the research for approximately 50 minutes if you 
are completing the questionnaires alone. You will be involved for a 
further 2 hours and 20 minutes if you complete the interview and repeat 
questionnaires. The research itself will last approximately 18 months. 
You will be asked to complete some questionnaires which ask about 
your mood and how you have been feeling over the last two weeks. You 
will also be asked to give some information such as your age, gender 
and when you were diagnosed with multiple sclerosis. You have been 
provided with a pre-paid envelope for you to return the completed 
information to a Research Associate.  
If you decide you are willing to take part in an interview then please 
complete the opt-in slip included, you may be contacted once your 
questionnaires have been returned. Not everyone that has stated they 
are willing to take part in an interview will be doing so. If you have 
agreed to take part in an interview but it is not necessary you will be 
informed by letter. If you have agreed to take part in an interview and it 
is felt it would be useful to the study the Research Associate will give 
your contact details to the Study Co-ordinator. The Study Co-ordinator 
will contact you to complete the interview. Once the interview is 
complete you will be asked to fill out a further set of questionnaires and 
return them by pre-paid envelope which will be provided. 
All the information you give will be identified by a unique study identity 
code to you in the study. Information that identifies you will be kept 
securely and separately from the information that is used in the study. 
The interview with the Study Co-ordinator will involve an audio 
recording, this will be copied onto a compact disc labelled with your 
unique number and kept securely, the original on the audio recorder will 
be deleted. The recording may be listened to by a Research Associate, 
this will be anonymous and the person listening to the recording will not 
have any other information about you. 
Expenses and payments 
You will not receive any payments for taking part in the study. The 
Study Co-ordinator will be travelling to meet you for the interview and so 
this will not be an expense. Any information that needs to be sent by 
post will be paid for by the study. 
What are the possible disadvantages and risks of taking part? 
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There is a possible risk that you may become distressed when taking 
part in the study. The study will require you to think about how you are 
feeling at the moment and there is a potential that this may be 
distressing for you. A list of organisations that may help you if you do 
become distressed is at the end of this information sheet. The study co-
ordinator will also bring the list of organisations to the interview. If you 
feel distressed following the study you may also wish to talk to staff 
within the Multiple Sclerosis service. 
What are the possible benefits of taking part? 
You will be given the opportunity to talk about how you are currently 
feeling and your mood at the moment. The information we get from this 
study will also help improve the treatment of people with a diagnosis of 
Multiple Sclerosis. 
What if there is a problem? 
Any complaint about the way you have been dealt with during the study 
or any possible harm you might suffer will be addressed. If you have a 
concern about any aspect of this study, you should ask to speak to the 
chief investigator who will do their best to answer your questions. If you 
remain unhappy and wish to complain formally, you can do this through 
the NHS Complaints Procedure by contacting the Patient Advice and 
Liaison Service on 0115 9249924 extension 65412, or the University of 
Nottingham on 0115 8467523. 
 
In the event that something does go wrong and you are harmed during 
WKHUHVHDUFKGXHWRVRPHRQH¶VQHJOLJHQFHWKHQ\RXPD\KDYHJURXQGV
for a legal action for compensation against the University of Nottingham 
but you may have to pay your legal costs. The normal National Health 
Service complaints mechanisms will still be available to you. 
What will I have to do? 
If you choose to take part in the study you will be asked to do a number 
of things. The steps involved are shown overleaf: 
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Will my taking part in the study be kept confidential? 
Yes. We follow ethical and legal practice and all information about you 
will be handled in confidence. All information which is collected about 
you during the course of the research will be kept strictly confidential 
and will be marked with a unique study identity code so no identifiable 
information will be on the questionnaires or interview recording. Your 
contact details and consent form will be placed in a sealed envelope, 
labelled with the name of the Study Co-ordinator, the identifier code 
given to you and the date it can be destroyed. This will be kept in a 
Read through this information sheet to 
decide if you want to take part in the 
study. Contact the Study Co-ordinator if 
you have any questions 
If you indicate you do 
not wish to have an 
interview that that is 
fine. You can contact 
the Study Co-ordinator 
if you have any 
questions at a later 
date. 
Contacted by Study Co-ordinator to arrange 
time and place to complete interview. Consent 
gained prior to interview. Complete interview. 
Receive 
letter of 
thanks but 
no interview 
is necessary 
Following interview complete 
questionnaires which are given to you 
at the interview and post them in the 
pre-stamped envelope. 
If you decide you do 
not wish to take part 
in the study that is 
fine. It will not affect 
the standard of care 
you receive. 
Complete all the questionnaires that have been 
sent to you and return them in the pre post 
envelope to the Research Associate in the pre 
stamped envelope. Please indicate if you would 
be willing to take part in an interview on the opt-
in slip. 
If you have indicated you would be willing to take 
part in an interview then you may or may not be 
contacted to take part in an interview.  
If you would like a 
summary of the 
results then 
please fill in the 
opt in slip. You 
will be sent a 
summary by 
February 2011. 
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locked filing cabinet at the University of Nottingham. The other 
information you provide will be kept in the same manner although parts 
of it may be placed onto a computer. If this is the case, then it will be 
encrypted and only the Research Associate and Study Co-ordinator will 
have access to it. Any information that has your name or address on it 
will not be accessed by anyone other than the Research Associate and 
Study Co-ordinator. All the data you provide will be kept for seven years 
after the study is complete, it will then be destroyed securely. 
:KDWZLOOKDSSHQLI,GRQ¶WZDQWWRFDUU\RQZLWKWKHVWXG\" 
You are able to withdraw from the study at any time without giving a 
reason, you just need to let the study co-ordinator know. Once the data 
has been collected by questionnaires or interview it cannot be erased 
but it will remain anonymous.  
What will happen to the results of the research study? 
The results of the study will be reported as part of the Study Co-
RUGLQDWRU¶V GRFWRUDO WKHVLV ,I \RX ZLVK WR UHFHLYH D VXPPDU\ RI WKH
results when the study has been completed then tick the box on the opt-
in slip and provide your contact details.. The Study Co-ordinator will use 
your contact details to send you a summary of the results in February 
2011.  
Who is organising and funding the research? 
The sponsor of the study is the University of Nottingham. 
Who has reviewed the study? 
All research in the NHS is looked at by independent group of people, 
called a Research Ethics Committee to protect your safety, rights, 
wellbeing and dignity. This occurs before the study begins and so they 
will not have access to any information about you. 
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Further Information and Contact Details 
You may still have some questions about this research project. If you 
wish to have further information the please use the contact details 
below for the study co-ordinator.  
Chief Investigator: Nadina Lincoln 
Study Co-ordinator: Tessa Hopkins 
Address:  Institute of Work, Health and Organisations 
Jubilee Campus 
Wollaton Road  
University of Nottingham 
NG8 1BB 
Telephone Number: 0115 8467523 
E-mail:   lwxth4@nottingham.ac.uk 
If you have any questions about participating in research in general or 
wish to make a complain using the NHS Complaints Procedure please 
contact the Patient Advice and Liaison Service on: 0115 9249924 
extension 65412. 
If you wish to make a complaint through the University of Nottingham 
please contact the Institute of Work and Organisations on: 0115 
8467523. 
If you feel distressed at any point due to your participation in the study 
the following are organisations that may help: 
 Samaritans: 08457 909090 
 Nottingham Multiple Sclerosis Society: 0115 9786745  
 Nottingham Counselling Service: 0115 9501743 
 Focus Line, support for anyone affected by mental health 
issues: 0800 027 2127 
 NHS Direct: 0845 46 47 
 
You may also wish to discuss your participation in the study with family, 
friends, and clinicians from the Multiple Sclerosis service or your GP. 
Thank you for reading this information sheet. If you have decided you 
want to take part in the study then please sign the consent form and 
complete all the questionnaires. These will be picked up by the study 
co-ordinator at the interview. 
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APPENDIX I: Demographic questions sent to participants 
     
  
DEMOGRAPHIC INFORMATION 
 
 
Please complete the following: 
 
Age (years): ______  
Gender: Male / Female 
Type of Multiple Sclerosis:  Primary Progressive 
Relapsing Remitting  
Secondary Progressive 
Time since diagnosis of Multiple Sclerosis: 
 _____ years  
 
